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ABSTRACT
The pancreas develops from the foregut endoderm through the fusion of dorsal and ventral
pancreatic buds. During development the pancreatic epithelium undergoes branching
morphogenesis, in which endoderm-mesoderm interactions are needed for differentiation. Gene
targeting experiments have shown the necessity of transcription factors for this process, but the
extracellular regulatory mechanisms are not well understood.
The major aim of this study was to elucidate the role of EGFR-, erbB4-, and FGFR2b-mediated
signaling in growth and differentiation of pancreatic endocrine progenitor cells.
First, effects of several growth factors were screened using INS-1 insulinoma cells. It was found
that betacellulin, a member of the EGF-family, induced proliferation of these cells. The importance
of EGFR-mediated signaling in pancreas development was further studied using mice that lack
functional EGFR. In EGFR deficient mice both the proliferation and the number of beta cells was
diminished. Also the migration of pancreatic islet cells from their embryonic ductal position was
impaired due to diminished gelatinolytic activity. In the next set of studies expression of erbB4,
another EGF-family receptor, and several EGF-family ligands were detected already at early phases
of pancreas development. To further study the role of EGFR and erbB4 in pancreas development,
several of their ligands were introduced to embryonic mouse pancreas cultures. In these
experiments the EGFR ligands EGF, HB-EGF and betacellulin induced differentiation of beta cells,
betacellulin being the most potent factor in this respect. NRG4, an erbB4 ligand, instead induced
delta cell development. Both betacellulin and NRG4 were inhibitory to alpha cell formation,
indicating that EGFR- and erbB4-mediated signaling favors the beta/delta cell lineages instead of
the alpha cell lineage.
Finally, the role of FGFR2b in pancreas development was defined by analyzing the pancreatic
phenotype of mice lacking functional FGFR2b. Pancreases of FGFR2b (-/-) mice were significantly
diminished in size, and both the pancreatic ductal branching as well as duct cell proliferation was
reduced. Differentiation of exocrine and endocrine cells on the other hand occurred normally.
Addition of FGFR2b ligands (FGF7 and FGF10) into wild type pancreatic organ cultures stimulated
duct cell proliferation. These findings suggest that FGFR2b-mediated signaling plays a major role
in pancreatic ductal proliferation and branching.
In conclusion, EGFR, erbB4, FGFR2b, and their ligands appear as important regulators of
pancreatic islet cell progenitors. Results obtained from these studies are directly linked to
development of islet transplantation therapies. Knowledge of factors regulating beta cell
differentiation, proliferation and survival is essential to be able to potently manipulate stem or
progenitor cells towards terminally differentiated physiologically regulated transplantable beta
cells.
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INTRODUCTION
Type 1 (insulin-dependent) diabetes mellitus (IDDM) is an autoimmune disorder where destruction
of insulin-producing pancreatic beta cells leads to insulin deficiency (Atkinson and Maclaren,
1994). There are currently approximately 70 000 type I diabetics in Finland (National Health
Institute, 2000), and the incidence of the disease has increased steadily, being higher than in any
other country (Karvonen et al., 2000). Current treatment of IDDM is based on insulin injection
therapy that, however, does not provide continuous normoglycemia to the patients. As a
consequence, long-term complications associated with the disease are a major reason for excess
morbidity and mortality of IDDM patients.
Transplantation of isolated pancreatic islets, or beta cells, is considered as a promising approach to
restore the required mass of functional beta cells in diabetic patients (Ricordi, 1996). Although
encouraging long-term success has been reported from clinical islet allotransplantation (Shapiro et
al., 2000), the major obstacle to a widespread clinical use of cell transplantation therapy in diabetes
is the lack of donor tissue. Thus, new sources of transplantable insulin-producing cells are needed.
Currently efforts are being made to generate insulin-producing cells from stem cells or tissue-
specific progenitor cells (Bonner-Weir et al., 2000; Lumelsky et al., 2001).
Formation of insulin-producing beta cells can take place by two pathways: via neogenesis of beta
cells from islet cell precursors or via replication of already existing beta cells. During fetal life
majority of new beta cells develop from precursor stem cells, but newly developed beta cells also
proliferate. In the adult pancreas the amount of both beta cell neogenesis and replication is more
limited, but however, takes place (Bonner-Weir et al., 1993; Bouwens et al., 1997; Tyrberg et al.,
1996). Understanding of the developmental biology and function of the pancreatic beta cell has
progressed rapidly during recent years, mainly through the cloning and functional analysis of
several tissue-specific transcription factors (Edlund, 1998; Sander and German, 1997). However,
extracellular factors, i.e. growth factors, regulating beta cell neogenesis and replication during fetal
as well as adult life remain in larger part unknown.
The following review of the literature first describes the ontogeny and transcriptional regulation of
pancreas development. Thereafter the focus will be on the role of growth factors and extracellular
matrix proteins in pancreas development, the major emphasis being on the role of epidermal growth
factor and fibroblast growth factor families.
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REVIEW OF THE LITERATURE
1. Overview of endocrine pancreas development
The mammalian pancreas is a mixed exocrine and endocrine organ that derives from the gut
endoderm. Mature mammalian pancreas is comprised of the exocrine ductal and acinar
compartment, which is responsible for the production and secretion of the digestive enzymes
(amylase, lipase, carboxypeptidase etc.), and the endocrine compartment, which is responsible for
the production of hormones controlling glucose homeostasis (insulin, glucagon, somatostatin and
pancreatic polypeptide). The exocrine portion comprises approximately 99% of the adult
mammalian pancreas. Endocrine cells, which comprise 1% of the total pancreatic mass, are located
in the islets of Langerhans. Mature islets of Langerhans are discrete micro-organs scattered
throughout the exocrine pancreas. They have a characteristic distribution of insulin-expressing cells
in the central core of the islets and the peripheral location of non-insulin cells. The human pancreas
contains about one million islets whilst in the mouse pancreas several hundred islets are detectable
(Hughes, 1956; Slack, 1995).
1.1. Morphogenic events and cytodifferentiation in the developing mouse pancreas
Morphologically evident pancreas development begins by appearance of the dorsal pancreatic bud
in the 3 mm long embryo, around the embryonic day 25 in human (Liu and Potter, 1962), and at
embryonic day 9.5 (e9.5) in mouse (Slack, 1995).
Appearance of the pancreatic bud is preceded by formation of the three germ layers, endoderm,
ectoderm and mesoderm by the end of gastrulation at e7.5 in the mouse. The endodermal germ
layer will give rise to the digestive tract and the organs that branch from the main tube, including
the pancreas. Before e8.5, the dorsal prepancreatic endoderm looses its contact with the notochord.
The dorsal mesenchyme underlying the future pancreatic area condenses and the adjacent duodenal
epithelium starts to evaginate forming the dorsal pancreatic bud at e9.5. Soon after (at e10.5) also
the ventral bud will arise. As both the dorsal and ventral buds have formed, the pancreatic epithelial
cells invade the surrounding mesenchyme. Mesenchymal signals stimulate proliferation, branching
and growth of the developing pancreatic epithelium, finally leading to a highly branched
differentiated organ where acinar and ductal structures are clearly distinguishable by e14.5. As
duodenum and stomach start to rotate, the ventral and dorsal pancreatic buds finally come into
contact and fuse around e17 to form a single organ (Figure 1) (Golosow and Grobstein, 1962;
Slack, 1995; Wessells and Cohen, 1967).
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Markers of endocrine cytodifferentiation can be detected at early phases of pancreas development.
Expression of somatostatin mRNA is detected in the mouse gut endoderm already at e7.5 - 8.5.
Glucagon and insulin mRNA expression can be detected at e8.5 - 9, and expression of PP mRNA
soon after that. The appearance of scattered cells with immunoreactivity for insulin or glucagon can
be seen at e9.5 but immunoreactivity for PP is found first at e18. Transcription of amylase and
carboxypeptidase is detected at e10.5 - 12, and immunoreactivity for amylase can be seen at e14.5
(Gittes and Rutter, 1992; Herrera et al., 1991). The early endocrine cells are associated with the
pancreatic ducts, and mature islets of Langerhans with central insulin-producing cells become
detectable first at around e18 – 19 (Figure 1). Formation of mature islets requires sorting of the
endocrine cells out of the ductal epithelium, migration of cells through the extracellular matrix, and
cell reaggregation, processes where cell adhesion is of importance.
Figure 1. Progression of the
mouse embryonic pancreas
development (Modified from
Edlund, 1998, Sander and
German, 1997 and Kemp et al.,
2003). Embryonic foregut
endoderm designated to
become pancreas starts to
express transcription factor
PDX1. Soon after both the
dorsal and ventral pancreatic
buds evaginate. Pancreatic
e p i t h e l i u m  b r a n c h e s ,
proliferates and invades the
surrounding mesenchyme.
Endocrine cells start to
d i f f e r e n t i a t e .  M a t u r e
pancreatic islets form around
birth.
It was previously suggested that pancreatic endocrine cells arise from common precursors co-
expressing islet hormones (Teitelman et al., 1987). Common islet progenitor cells have also been
shown to express peptide YY (Upchurch et al., 1994) or neuropeptide Y (Teitelman et al., 1993). It
has also been shown that early embryonic endocrine cells in the duct wall transiently express
tyrosine hydroxylase (TH) (Teitelman and Lee, 1987). More recently, it was proposed that cells co-
expressing insulin and glucagon represent subpopulations of alpha cells that are capable for
pancreatic islet
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transient insulin expression, and that both alpha and beta cells develop independently (Jensen et al.,
2000a). This was verified by transgenic cell marking analysis by Herrera (Herrera, 2000).
Additional markers for pancreatic endocrine multipotent precursors have been suggested. The most
commonly accepted marker is cytokeratin (CK), which is specifically expressed by the pancreatic
ductal epithelial cells (Bouwens et al., 1994). In addition, it has been suggested that nestin, which is
a marker for neural stem cells, also marks pancreatic islet stem cells (Zulewski et al., 2001). It was
later shown that nestin is expressed in the mesenchymal cells of the developing pancreas, but not in
the pancreatic epithelial cells believed to represent the pancreatic progenitor cell pool (Selander and
Edlund, 2002). Other novel pancreatic markers include ghrelin, which was initially isolated from
the rat stomach as a ligand for the growth hormone secretagogue receptor (GHS-R). Ghrelin is
expressed in the human pancreatic islets from early gestation to adulthood. Ghrelin positive islet
cells do not express any of the known islet hormones (insulin, glucagon, somatostatin, or PP), and
thus seem to constitute a new islet cell type (Wierup et al., 2002).
The dorsal and ventral pancreas initially develop separately and then fuse at the later phase of
gestation to form a single organ (Liu and Potter, 1962). In adult mammals islet composition and
function differ in dorsal and ventral part of the pancreas. In the dorsal islets number of glucagon
producing alpha cells is significantly higher than in ventral islets, whereas majority of PP cells are
located in the ventral islets. Beta cell number is similar both in the dorsal and ventral pancreatic
lobes, however, glucose-stimulated insulin secretion and proinsulin biosynthesis are significantly
higher in the dorsal islets (Baetens et al., 1979; Trimble et al., 1982).
2. Genetic regulation of pancreas development
Differentiation of early gut endoderm cells into fully mature endocrine and exocrine pancreatic cells
is under strictly regulated genetic control. Already pioneer studies in the area of islet development
stressed the importance of epithelial-mesenchymal interactions in the early pancreas development
(Golosow and Grobstein, 1962; Pictet and Rutter, 1972; Wessells and Cohen, 1967). Recently, also
the molecular mechanisms underlying pancreatic differentiation have started to become clarified.
2.1. Initiation of the pancreatic program
Early development events of ventral and dorsal pancreatic domains are independent. Signals from
the notochord are important for development of the dorsal pancreas, whereas signals from the
adjacent endothelial cells seem to be necessary for the initiation of both dorsal and ventral
pancreatic development. The early endoderm is in tight contact with endothelium of the dorsal aorta
and vitelline veins. Followingly, the dorsal and ventral pancreatic buds start to develop precisely
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where endoderm previously contacted the endothelium. It has also been shown that isolated
endoderm does not start expression of pancreatic markers unless it is cultured with endothelium.
Also development of the liver has been shown to be dependent on close vicinity of the endothelium
(Lammert et al., 2001; Lammert et al., 2003). The liver and the ventral pancreas are specified at the
same time from the same group of ventral foregut cells that express the homeobox gene Prox1
(Burke and Oliver, 2002). FGF signaling from the cardiac mesoderm induces local expression of
sonic hedgehog (Shh) on ventral endoderm. Shh in turn is inhibitory to pancreas but permissive to
liver development. Close vicinity of the cardiac mesoderm thus seems to be inhibitory for the
initiation of ventral pancreas development. As ventral endodermal cells are cultured without cardiac
mesoderm they start to express pancreatic marker PDX1 (see below) and fail to express liver
markers (Deutsch et al., 2001). Dorsal prepancreatic endoderm is in tight contact with the adjacent
notochord until the dorsal aorta fuse. This interaction of endoderm with notochord is necessary for
proper dorsal pancreas formation. Notochord secretes inducing molecules (at least FGF2 and
activin-bB) that permit initiation of the pancreatic program. Factors secreted by the notochord are
responsible for inhibition of expression of hedgehog family signaling molecules in the adjacent gut
endoderm. It has been shown that repression of both sonic hedgehog and indian hedgehog in the
prepancreatic endoderm is necessary for the continuation of pancreatic differentiation. Both sonic
and indian hedgehog are uniformly expressed in the gut endoderm anterior and posterior to the
pancreas, however, they remain selectively excluded from the pancreatic buds throughout the
development. Also later ectopic expression of Shh in the mouse pancreas prevents proper pancreatic
morphogenesis (Apelqvist et al., 1997; diIorio et al., 2002; Hebrok et al., 1998; Hebrok et al., 2000;
Kim et al., 1997).
 2.2. Transcriptional regulation of pancreas development
A number of transcription factors have been implicated in pancreas development. These belong to
the homeodomain family (Pdx1, Hb9, Pbx1, HNF6, Pax4, Pax6, Nkx2.2, Nkx6.1, Isl1, HNF1a,
HNF4a, Brn4), the basic helix-loop-helix (bHLH) family (Ngn3, NeuroD, Hes1, p48) and the
forkhead/winged helix family (Foxa2/HNF3b, Foxa1/HNF3a). Several homeodomain and bHLH
transcription factors have a central role in controlling pancreatic endocrine differentiation, and are
expressed already at early stages of pancreas development (Table 1 and Figure 2).
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Figure 3. A simplified model for the hierarchy of transcription factor expression in the developing pancreas. The
proposed position for each transcription factor is based on its timing of expression or timing of predominant functional
role (modified from Edlund, 1998 and Kemp et al., 2003).
Pancreatic duodenal homeobox 1 (Pdx1) [human gene known as insulin promoter factor 1 (Ipf1)] is
a homeodomain transcription factor with a key regulatory role both in pancreas development and in
adult beta cell function. During mouse embryogenesis PDX1 is first detected at e8.5 in the ventral
gut endoderm in cells later forming the ventral pancreatic bud. At e9.5 PDX1 is expressed both in
the dorsal and ventral pancreatic buds, and during early pancreas development its expression is
detected throughout the developing pancreatic epithelium. PDX1 expressing cells give rise to all
pancreatic cell types: exocrine, endocrine and duct cells. Later in life PDX1 expression becomes
restricted to beta and delta cells of the islets of Langerhans, and in dispersed endocrine cells of the
duodenal wall (Guz et al., 1995; Jonsson et al., 1994). In the adult pancreas PDX1 acts as a key
regulator of insulin gene expression (Ohlsson et al., 1993), and beta cell specific gene disruption of
Pdx1 results in reduced beta cell mass and diabetes (Ahlgren et al., 1998). Heterozygous mutations
in human Ipf1 gene have also been shown to cause MODY-type adult-onset diabetes (Stoffers et al.,
1997a), and homozygous Ipf1 mutations cause agenesis of the pancreas (Stoffers et al., 1997b). In
mice carrying a null mutation of Pdx1, pancreatic development is arrested at very early stage.
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However, the initial stages of pancreatic bud formation occur and early insulin- and glucagon-
producing cells appear (Ahlgren et al., 1996; Jonsson et al., 1994). This points to the existence of
additional upstream regulators of Pdx1 (McKinnon and Docherty, 2001). In any case, the
expression of PDX1 in gut endoderm is crucial for the pancreatic program to continue and all
pancreatic tissues subsequently differentiate from PDX1-positive precursors.
Forkhead/winged helix transcription factor Foxa2 (formerly known as Hnf3b) has been shown to
be a key regulator of early foregut development and also to act as an upstream regulator of Pdx1
(Lee et al., 2002). FOXA2 is expressed in the early foregut endoderm, and also in the adult
pancreatic islet and acinar tissue (Wu et al., 1997). Pdx1 promoter region has binding sites for
FOXA2, and it has been shown that FOXA2 acts as a transcriptional regulator of Pdx1. However,
also other activators of the Pdx1 gene must exist since beta cell specific deletion of Foxa2 does not
totally arrest PDX1 expression (Lee et al., 2002; Sund et al., 2001). FOXA1 (formerly HNF3a) is
initially expressed in the notochord and later on in all pancreatic islet cell types. In mice deficient
for FOXA1 expression of proglucagon gene is reduced and mice die between P2 and P12 due to
hypoglycemia (Kaestner et al. 1999).
Another homeobox gene having a key regulatory role in early pancreas development is Hlxb9
(encoding HB9). HB9 is expressed at the early stages of mouse pancreatic development and later in
life in the mature beta cells. HB9 expression is first seen at e8 in the notochord, dorsal gut
endoderm and ventral prepancreatic endoderm. In the dorsal pancreatic bud, expression of HB9
precedes expression of PDX1, whereas in the ventral bud both transcription factors appear
simultaneously. HB9 expression is detectable in both the dorsal and ventral pancreatic buds at e9.5.
At e10.5, its expression becomes restricted to the dorsal pancreatic bud, and then ceases. At later
stages when mature islets appear, HB9 can be detected in the mature beta cells. In mice deficient for
Hlxb9, dorsal pancreatic bud fails to initiate its development, but ventral pancreas development
starts normally. The ventral pancreatic epithelium generates all pancreatic cell types even in the
absence of Hlxb9. However, the number of beta cells is decreased and islet cell organization
perturbed. Persistent expression of Hlxb9 under the Pdx1 promoter leads to agenesis of both dorsal
and ventral pancreas. This indicates that spatially and temporally regulated expression of Hlxb9 is
necessary for proper pancreas development (Harrison et al., 1999; Li et al., 1999; Li and Edlund,
2001).
PBX1 is expressed at e10.5 both in the mesenchymal cells adjacent to pancreatic buds and in the
PDX1 positive pancreatic epithelial cells. At e14.5 PBX1 is expressed in the ductal epithelial cells,
pancreatic mesenchymal cells, and in early exocrine cells. In the adult pancreas PBX1 expression is
detected in ductal, endocrine and exocrine cells. In mice deficient for PBX1, pancreas is hypoplastic
and both exocrine and endocrine differentiation is impaired. Thus, also PBX1 seems to be essential
for normal pancreatic development (Kim et al., 2002).
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Hepatocyte nuclear factor 6 (Hnf6) is a homeodomain transcription factor that is expressed in the
epithelial cells of the pancreas starting at e9.5. Later, the expression of HNF6 is restricted to acinar
and ductal cells. In mice deficient for HNF6, exocrine pancreas appears to develop normally but
endocrine differentiation is impaired. Expression of the pro-endocrine gene Ngn3 (see below) is
almost abolished. It has also been shown that HNF6 binds to and stimulates the Ngn3 promoter.
HNF6 has previously been suggested to be a regulator of PDX1 and FOXA2. Their expression,
however, is normal in HNF6 (-/-) pancreas (Jacquemin et al., 2000).
Hepatocyte nuclear factor 1a (HNF1a) and HNF4a have been shown to underlie two types of
maturity-onset diabetes of the young (MODY) in human. MODY3 results from the mutations in
Hnf1a, and MODY1 from the mutations in Hnf4a, which is a regulator of Hnf1a. In humans with
heterozygous Hnf1a or Hnf4a mutation, insulin-secretion is impaired, leading to diabetes. In mice,
carrying heterozygous mutations for Hnf1a or Hnf4a, pancreatic function is normal, however in
HNF1a (-/-) mice a similar phenotype to human MODY3 exists. Expression of HNF1a is first
detected at e10.5 in the dorsal pancreas of the developing mouse. From e15.5 onwards expression
can be seen in all pancreatic cell types, both exocrine and endocrine (Ferrer, 2002; Nammo et al.,
2002; Pontoglio et al., 1998; Shih et al., 2001).
Pancreatic endocrine cells develop from precursor cells expressing PDX1 and the bHLH-family
transcription factor neurogenin3 (NGN3). All four islet cell types develop from NGN3 expressing
cells that are found adjacent to ductal cells. However, coexpression of NGN3 with islet hormones
(insulin, glucagon, somatostatin, PP) can not be detected. NGN3 expression is first observed at
e9.5, and the number of NGN3 expressing cells increases until e15.5 - the time-point when islet cell
differentiation peaks - and decreases thereafter. In the adult pancreas NGN3 positive cells are
expressed within the endocrine islets and may represent pancreatic progenitor cells. In mice
deficient for NGN3, all four islet cell types are missing at all stages of development. However, both
exocrine and ductal tissues develop normally. Expression of NGN3 is strictly controlled. Its
promoter has binding sites for HES1, which is a transcriptional repressor of bHLH genes and thus
inhibits NGN3 expression. Also HNF6, FOXA2 and HNF1a bind to the Ngn3 promoter, acting as
its activators. NGN3 on the other hand acts as an upstream regulator for the transcription factors
Pax6, Pax4, NeuroD, Nkx6.1, Nkx2.2 and Isl1 (Gradwohl et al., 2000; Gu et al., 2003; Gu et al.,
2002; Lee et al., 2001).
NeuroD, a bHLH factor, is an important activator of insulin gene transcription, but is also required
for generation of a normal mass of pancreatic beta and alpha cells. One of the earliest steps in the
pancreatic endocrine differentiation is activation of NeuroD expression in cells coexpressing NGN3
and PDX1. NGN3 is an upstream activator of NeuroD, and though these two factors are expressed
in different cells, it has been demonstrated that NeuroD-positive cells arise from cells expressing
NGN3. NeuroD expression is detected at e9.5 in early glucagon expressing cells. Inactivation of
NeuroD gene in mice leads to lethality 3-5 days postpartum due to severe hyperglycemia. In
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newborn NeuroD (-/-) mice the number of beta cells is reduced by 75%, also numbers of alpha and
delta cells are reduced (Jensen et al., 2000a; Naya et al., 1997).
NGN3
NeuroD
Delta Notch
HES
+
+
+
NGN3
Delta
Notch
–
HES
+
Endocrine differentiation Progenitor cell proliferation
–
–
Figure 3. Lateral inhibition of neurogenin3 expression. NGN3 activation leads to endocrine differentiation of
pancreatic progenitor cells and also to activation of Delta-Notch pathway. Activation of Notch-pathway causes
activation of HES-type proteins that act as lateral inhibitors of NGN3 expression and thus allow expansion of pancreatic
progenitor cell pool (Modified from Apelqvist et al., 1999, Jensen et al., 2000b).
bHLH proteins NGN3 and NeuroD are antagonized by the Notch pathway. Activation of Notch
receptors leads to activation of Hairy and Enhancer-of-split (HES) -type proteins, which in turn act
as transcriptional repressors of bHLH genes. Mice lacking Notch ligand Delta like-1 (Dll1) or the
DNA-binding protein RBP-jk, which is an activator of HES1, have accelerated differentiation of
pancreatic endocrine cells and subsequently severe pancreatic hypoplasia due to premature
differentiation of pancreatic stem cells into endocrine cells. Also mice overexpressing NGN3 and
mice lacking HES1 have a similar pancreatic phenotype. Lateral inhibition of NGN3 expression via
Notch-pathway is necessary to allow the expansion of epithelial cells prior to differentiation (Figure
3). Premature overexpression of NGN3 will block the Notch-pathway, which then results into
poorly branched ductal epithelium, blockage of exocrine development, and accelerated islet cell
differentiation. The Notch signaling pathway is thus involved in the regulation of the balance
between progenitor cell differentiation and proliferation during the pancreas development
(Apelqvist et al., 1999; Jensen et al., 2000b; Lammert et al., 2000).
PTF1-p48 encodes a bHLH protein that is a 48 kD pancreas-specific subunit of the trimeric
pancreas transcription factor PTF1. PTF1-p48 has been considered as the only known exocrine
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pancreas-specific transcriptional regulator. Recently, however, PTF1-p48 was shown to regulate
commitment of foregut cells, and majority of progenitors of islets, acini and ducts express PTF1-
p48. PTF1-p48 seems to have an important role in determining whether prepancreatic cells continue
pancreatic organogenesis or differentiate towards intestinal phenotypes. PTF1-p48 was previously
considered as an exocrine transcription factor because mice homozygous for a null mutation of the
p48 allele totally lack the exocrine pancreas. The ductal epithelium of the p48 (-/-) mice fails to
grow and branch and although the endocrine pancreatic cells are formed, they disappear from their
original location and migrate to the spleen later during development (Kawaguchi et al., 2002; Krapp
et al., 1996; Krapp et al., 1998).
Islet-1 (Isl1) encodes a transcription factor belonging to the LIM homeodomain family. ISL1
expression is first detected at e9-9.5 in mesenchymal cells surrounding the dorsal pancreatic bud,
and in glucagon positive cells. All developing pancreatic islet cells are positive for ISL1 expression
and ISL1 is also expressed in all adult endocrine cells. In mice lacking ISL1, development of the
dorsal pancreatic mesenchyme fails and subsequently there is also a failure in the development of
the exocrine cells in the dorsal pancreas. In Isl1 (-/-) mice there is also a complete loss of all islet
cell types (Ahlgren et al., 1997).
Brain-4 (BRN4) is a member of pou-homeodomain proteins and is expressed in pancreatic
epithelial progenitor cells that later differentiate into glucagon producing alpha cells. Expression of
BRN4 precedes expression of ISL1 and expression of BRN4 appears to be the early sign of alpha
cell development (Hussain et al., 2002).
Pax4 and Pax6 are paired box genes belonging to the Pax gene family. PAX4 and PAX6 are
closely related and have also been implicated in the pancreas development. PAX6 is expressed in a
subset of cells in the developing pancreas already at e9. PAX4 is detected in the developing mouse
pancreas at e9.5. During the secondary transition stage (at e14.5) the number of PAX4 expressing
cells increases significantly. At this point some of the PAX4 positive cells coexpress insulin. In the
adult pancreas PAX4 expression is no longer detectable. PAX6 instead is expressed in all endocrine
cells of the developing pancreas as well as in all mature endocrine cells. Mice lacking a functional
Pax4 gene die within three days of birth. Macroscopically, their pancreas appears normal, but both
the insulin-producing beta cells as well as the somatostatin-producing delta cells are absent. Instead,
the number of glucagon-producing alpha cells is increased. Early pancreas development appears to
be normal in Pax4 (-/-) embryos, but their endocrine progenitor cells fail to mature into beta or delta
cells. Also the markers of mature beta cells are absent. In mice lacking PAX6, mature beta, delta
and PP-cells can be found, but their number is reduced and the islet formation is disrupted. Cells
expressing glucagon are totally abolished. Exocrine differentiation, in contrast, appears to be
normal. Mice lacking both PAX4 and PAX6 fail to develop any endocrine cells, suggesting that Pax
genes are essential for endocrine cell differentiation during pancreatic development (Dohrmann et
al., 2000; Sosa-Pineda et al., 1997; St.Onge et al., 1997).
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Table 1. Major pancreatic transcription factors, their expression and functions
Transcription
factor
Onset and site of pancreatic
expression
Mouse & human mutations References
Homeodomain factors
Pdx1 e8.5, early pancreatic
epithelium, beta and delta
cells of mature pancreas
Pancreatic agenesis,
heterozygous human
mutation: MODY4
Guz et al., 1995; Jonsson et al., 1994;
Ohlsson et al., 1993; Ahlgren et al.
1998; Stoffers et al. 1997a, b
Hb9 e8, early prepancreatic
endoderm, mature beta cells
Dorsal pancreatic agenesis Harrison et al., 1999; Li et al., 1999;
Li and Edlund 2001
Pbx1 e10.5, ubiquitous Hypoplastic pancreas Kim et al., 2002
HNF6 e9.5, throughout the
pancreatic buds
Impaired endocrine
differentiation
Jacquemin et al., 2000
Pax4 e9.5, in developing
endocrine cells, not found in
mature pancreas
Deficiency of beta and
delta cells, increase in
alpha cells
Dohrmann et al., 2000; Sosa-Pineda et
al., 1997
Pax6 e9, in endocrine cells No alpha cells, decrease in
other endocrine cell types
St-Onge et al., 1997
Nkx2.2 e9.5, throughout pancreatic
bud, later in endocrine cells
Lack of beta cells, decrese
in alpha and PP cells
Sussel et. al, 1998
Nkx6.1 e9.5, in beta cells Decrease in beta cells Sander et al., 2000
Isl1 e9, in all islet cells No differentiated islet cells Ahlgren et al., 1997
HNF1a e10.5, dorsal pancreas,
mature beta cells
Heterozygous human
mutation and homozygous
mouse mutation: MODY3
Nammo et al., 2002; Pontoglio et al.,
1998
HNF4a e5.5, in visceral endoderm,
e9.5 in pancreatic
primordium
Early embryonic lethal
Heterozygous human
mutaion: MODY1
Ferrer, 2002; Duncan et al., 1994
Brn4 e9, in alpha cell progenitors No phenotype Hussain et al., 2002
Basic helix-loop-helix factors
Ngn3 e9.5, endocrine precursors No endocrine cells Gradwohl et al., 2000; Gu et al., 2002
NeuroD e9.5, endocrine precursors
and adult islet cells
Impaired islet development Jensen et al., 2000a; Naya et al., 1997
Hes1 e9.5, pancreatic precursors Premature endocrine
differentiation
Jensen et al., 2000b; Apelqvist et al.,
1999
Ptf1-p48 e10, exocrine, endocrine and
ductal progenitors
No exocrine cells Kawaguchi et al., 2002; Krapp et al.,
1996; Krapp et al., 1998
Forkhead / winged helix factors
Foxa2 / HNF3b e5.5-6.5, early foregut
endoderm, adult acinar and
islet tissue
Lack of foregut formation Lee et al., 2002; Sund et al., 2001
Foxa1 / HNF3a e7.5, notochord, later in all
islet cell types
Reduced proglucagon
expression
Kaestner et al., 1999
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Expression of NK homeodomain gene Nkx2.2 is initially detected at e9.5 in the pancreatic
epithelium, and during the following days NKX2.2 expression persists in most pancreatic cells. By
e15.5 NKX2.2 expression becomes restricted to the endocrine cells, and in the adult pancreas its
expression is detected in beta, alpha and PP-cells, but not in delta cells. NKX6.1 is initially
expressed in the developing pancreas at e10.5 in the majority of developing epithelial cells. By
e15.5 NKX6.1 expression becomes restricted to the insulin-expressing cells. All NKX6.1
expressing cells coexpress NKX2.2. In mice deficient for NKX2.2 exocrine pancreas develops
normally, but there is a reduction in islet-cell mass and islet morphology is disrupted. In NKX2.2 (-
/-) mice insulin producing beta cells are absent, the number of glucagon-producing alpha cells is
diminished and also the number of PP-cells is reduced. However, mutant pancreases contain a large
population of islet cells that express some beta cell specific markers, but do not produce any
pancreatic hormones. In mice lacking Nkx6.1 the gross pancreatic morphology appears normal,
however, the pancreatic islets are smaller. Expression of glucagon, somatostatin and PP is normal
but the number of insulin-producing cells is diminished. Expression of NKX2.2 is maintained in the
Nkx6.1 mutants, whereas expression of NKX6.1 is absent in the Nkx2.2 mutants, suggesting that
NKX6.1 acts downstream of NKX2.2 in beta cell development (Sander et al., 2000; Sussel et al.,
1998).
3. Soluble regulatory molecules and microenvironment in pancreas development
Knowledge of ontogeny and transcriptional regulation of endocrine pancreas development has
increased significantly during recent years. However, factors and mechanisms regulating the lineage
differentiation of islet cells from multipotent precursors are much less well understood. Two types
of co-operative signals are known to regulate cell proliferation, differentiation and survival: 1)
signaling by soluble regulatory molecules (i.e. hormones and growth factors) and 2) cell-associated
signals delivered by extracellular matrix (ECM) proteins and their receptors.
Endocrine differentiation of pancreatic islets has classically been thought to be induced by
interaction of the mesenchymal cells with the adjacent epithelium (Hellerström and Swenne, 1985;
Pictet and Rutter, 1972). More recently, it has been found that embryonic pancreatic epithelium
forms islets even without contact to the fetal mesenchyme, suggesting that the endocrine pancreas is
developing by default. However, signals derived from the mesenchyme and extracellular matrix are
important for the proper morphology, growth and development of the entire organ, including ducts
and acinar components of the pancreas (Gittes et al., 1996). Extracellular molecules also have an
important regulatory role during the adulthood since it has been shown that neogenesis of islets
from precursor cells occurs even in the adult pancreas. This has been clearly demonstrated in rodent
models of pancreas regeneration (Vinik et al., 1996) and is suggested by autopsy observations in
humans (Gepts, 1965).
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3.1. Factors regulating beta cell replication and neogenesis
Beta cell mass can be stimulated to increase by normal physiological demands (e.g. obesity or
pregnancy), by several pathological conditions (e.g. partial pancreatectomy or pancreatic islet
inflammation), as well as in experimental conditions by nutrients (e.g. glucose and some amino
acids) and growth factors (e.g. growth hormone and prolactin) (Bonner-Weir et al., 1983; Gu and
Sarvetnick, 1993; Swenne et al., 1980). There are two pathways for increased beta cell mass:
replication of pre-existing beta cells or neogenesis from stem cells. During fetal life, beta cells have
a high capacity for replication, but majority of new beta cells is formed by neogensis from
pancreatic ductal epithelial stem cells. Some of beta cells’ proliferative potential is retained also in
adulthood and beta cell neogenesis can be detected even in the adult pancreas. Glucose is an
important stimulator of beta cell replication in both fetal and adult life (Hellerström and Swenne,
1985) but also several other factors are involved.
Lactogenic and somatotropic hormones can induce beta cell replication. This is best demonstrated
by the fact that during pregnancy hyperplasia of pancreatic islets can be observed both in rodents
and in humans. This is a direct effect of increased lactogenic or somatotropic activity in islets, and
is mediated by placental lactogen (PL), prolactin (PRL) and growth hormone (GH), whose
circulating levels are increased in pregnancy. Expression levels of receptors for prolactin and
growth hormone, which also act as receptors for PL, are also elevated in pancreatic tissue from
pregnant rats (Moldrup et al., 1993). PL has been implicated as the most potent inducer of enhanced
islet cell mass during pregnancy. This effect is mediated via the PRL/GH receptor family,
stimulating the Jak/Stat intracellular signaling pathway. Similarly, PRL, PL and GH induce both
beta cell proliferation as well as insulin secretion in vitro (Brelje and Sorenson, 1991; Friedrichsen
et al., 2001; Nielsen, 1982; Nielsen et al., 1999). Unlike in several other tissues, it appears that the
effects of PRL, PL and GH in islets are IGF-I (insulin like growth factor-I) independent (Billestrup
and Nielsen, 1991; De et al., 1995). In vivo effects of PRL on beta cells have been studied using
mice overexpressing prolactin under the rat insulin II promoter (RIP). In these mice increased islet
cell mass can be detected, mainly due to enhanced beta cell proliferation (Vasavada et al., 2000).
Instead, in mice deficient for PRL receptor a clear reduction in beta cell mass is found. Also the
islet size is reduced in PRLR (-/-) newborn mice as compared to wild type littermates. PRLR (-/-)
mice are not diabetic, but their insulin secretory response to glucose is somewhat blunted (Freemark
et al., 2002).
Insulin-like growth factors (IGFs) and insulin, which are considered as important regulators of
organ growth in the developing fetus, are strong stimulators of beta cell replication and hypertrophy
(Rabinovitch et al., 1982; Swenne et al., 1987). Insulin-like growth factors (IGF-I and IGF-II) share
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a high degree of sequence homology with insulin and are produced by pancreatic islet cells both
during development and tissue regeneration (Smith et al., 1991). Also receptors for IGFs are
expressed by islet cells (Vanschravendijk et al., 1987). Both IGF-I and IGF-II can induce islet cell
growth in the developing pancreas (Otonkoski et al., 1988; Rabinovitch et al., 1982). IGF-II seems
to be stronger stimulator of beta cell growth than IGF-I and in mice overexpressing IGF-II the size
of pancreatic islets is increased due to induced islet cell proliferation and diminished apoptosis
(Petrik et al., 1998; Petrik et al., 1999). In mice lacking IGFR1 a reduction in the islet cell mass can
be observed, similar phenotype is observed in mice heterozygous for IGFR1 and lacking insulin
receptor substrate 2 (IGFR1+/-IRS2-/-) (Withers et al., 1999). In mice with beta cell specific
deletion of IGFR1, islet cell mass is normal, but beta cells have reduced expression of Glut2 and
glucokinase. This leads to defective glucose-stimulated insulin secretion and impaired glucose
tolerance (Kulkarni et al., 2002), suggesting that IGFR1 is not essential for pancreatic islet
development, but is involved in the regulation of beta cell function.
Hepatocyte growth factor/scatter factor (HGF/SF) is a mesenchyme-derived protein originally
identified as a liver regeneration factor (Nakamura et al., 1989). C-met tyrosine kinase, the receptor
for HGF, is expressed in epithelial cells of various developing organs and HGF is produced by
distinct mesenchymal cells in close vicinity, suggesting that HGF and c-met mediate epithelial-
mesenchymal interactions during development (Sonnenberg et al., 1993). Both HGF and c-met are
expressed in the developing pancreas (Defrances et al., 1992). In developing human pancreas c-met
expression is mainly associated with the developing beta cells and in the adult pancreas expression
is restricted to the islet beta cells (Otonkoski et al., 1996). In NOD (non-obese diabetic) mice
expression of c-met can be detected in ductal cells that are also positive for insulin (Bulotta et al.,
2001). Exogenous HGF is mitogenic for the human fetal pancreatic beta cells in vitro (Otonkoski et
al., 1994), this effect can be obtained also with medium secreted by fetal fibroblasts and can be
blocked by HGF neutralizing antibody (Otonkoski et al., 1996). In one study HGF together with
extracellular matrix was demonstrated to be mitogenic for adult human pancreatic beta cells in vitro
(Hayek et al., 1995), in another study, however, it appeared that the increase was in the proliferation
of duct cells (Lefebvre et al., 1998). Mice overexpressing HGF under the rat insulin II promoter
(RIP-HGF) show increase in the islet cell mass as well as in the beta cell proliferation. Insulin
content per beta cell is increased and insulin secretion in response to glucose is also higher in RIP-
HGF mice. Increase in the beta cell number and insulin content is associated with mild
hypoglycemia and hyperinsulinemia in these mice. In addition, islets isolated from RIP-HGF mice
function more effectively after transplantation (Garcia-Ocana et al., 2000; Garcia-Ocana et al.,
2001). In addition to several studies indicating HGF as a mitogenic factor for beta cells, it has been
shown to induce transdifferentiation of exocrine cell line into insulin-producing cells (Mashima et
al., 1996b).
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Transforming growth factor b (TGF-b) family contains more than 60 family members that regulate
cell proliferation, differentiation, morphogenesis and tissue remodeling starting from early
embryogenesis. Members of the TGF-b family are subdivided into bone morphogenetic proteins
(BMPs), TGF-bs, activins and inhibins, growth and differentiation factors (GDFs) and Müllerian
inhibiting substance. These factors signal via two receptor serine/threonine kinase subclasses, type I
(activin receptor-like kinase, ALK) and type II. Ligand binding to type II receptor leads to
activation of the type I receptor kinase that subsequently phosphorylates cytoplasmic Smad
proteins. Activated Smads enter the nucleus and act as transcriptional activators of target genes
(Massagué J. and Chen, 2000).
TGF-b and activin are expressed in the developing pancreas (Crisera et al., 2000; Furukawa et al.,
1995; Sanvito et al., 1994), as well as in the adult pancreatic tissue (Ogawa et al., 1993; Yamanaka
et al., 1993). Exogenously added TGF-b inhibits pancreatic acinar development and promotes
development of endocrine cells in embryonic mouse pancreas cultures (Sanvito et al., 1994). TGF-b
also has a role in regulating islet morphogenesis in developing pancreas. It activates matrix
metalloproteinase MMP-2 (see below), which in turn is necessary for islet morphogenesis (Miralles
et al., 1998). Exogenous activin has been shown to inhibit epithelial branching morphogenesis of
mouse embryonic pancreas rudiments in embryonic organ culture. This effect of activin is
neutralized by follistatin (Ritvos et al., 1995), which is expressed in the pancreatic mesenchyme
(Miralles et al., 1998), and is a known inhibitor of activins. Follistatin can also stimulate exocrine
pancreas development and inhibit endocrine differentiation in embryonic rat pancreatic epithelial
culture in vitro (Miralles et al., 1998) thus mimicking the effects of mesenchyme (Gittes et al.,
1996). Activin A has also been shown to have a potential to convert pancreatic exocrine AR42J cell
line into neuroendocrine direction (Ohnishi et al., 1995). As e15.5 mouse pancreatic cells are
cultured in the presence of laminin-1 and bone morphogenetic proteins 4, -5 or -6, formation of
cystic epithelial E-cadherin-positive cell clusters containing insulin-positive cells is promoted
(Jiang et al., 2002).
Expression of type II activin receptors ActRIIA and ActRIIB has been demonstrated in the
developing pancreas and also in the pancreatic islets of adult mice (Kim et al., 2000). Also type I
activin receptors are expressed in the pancreas, most abundantly ALK7 (Watanabe et al., 1999),
which also can induce phosphorylation of Smad2 in MIN6 mouse insulinoma cell line (Bondestam
et al., 2001). Mice lacking both type II activin receptors (ActRIIA-/-B-/-) show defects in foregut
patterning. In ActRIIA+/-B-/- embryos Shh is inappropriately expressed adjacent to pancreatic area
thus disturbing pancreas development. Expression of Isl1 is also downregulated, and islets that are
formed are reduced both in size and number. However, expression of exocrine markers is not
affected. (Kim et al., 2000) In transgenic mice expressing mutant forms of activin receptors
pancreatic islets are hypoplastic. Both in mice carrying a mutation of constitutively active activin
receptor I (i.e. too high activin effect) and in mice carrying a serine/threonine kinase defective
mutation in activin receptor II (i.e. no activin effect), the islet mass was diminished (Yamaoka et al.,
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1998). Also in transgenic mice expressing truncated type II activin receptor proper formation of
pancreatic islets is disturbed (Shiozaki et al., 1999).
Several additional factors have been implicated both in beta cell replication, differentiation as well
as in the regulation of beta cell turnover or apoptosis.
Nicotinamide, which is an inhibitor of poly (ADP-ribose) polymerase, has been shown to induce
beta cell differentiation in in vitro culture of both human (Otonkoski et al., 1993) and porcine
(Otonkoski et al., 1999) fetal pancreatic islets. Nicotinamide has also been used for the induction of
beta cell differentiation in cultured adult human pancreatic cells (Bonner-Weir et al., 2000) and to
prevent diabetes in experimental animal models (Uchigata et al., 1983; Yamada et al., 1982).
Though nicotinamide was not effective in preventing the onset of IDDM in first-degree relatives of
type 1 diabetics (the ENDIT trial) (Schatz and Bingley, 2001), nicotinamide has so far proven to be
the most potent in vitro inductor of beta cell differentiation. Sodium butyrate has also been shown
to potently increase insulin content of fetal porcine pancreatic islets when it is used in combination
with nicotinamide (Korsgren et al., 1993; Otonkoski et al., 1999).
Parathyroid hormone-related protein (PRTrP) and its receptors are expressed in the pancreatic islet
cells (Drucker et al., 1989). In mice overexpressing PTHrP under the rat insulin II promoter islet
cell hyperplasia, as a result of decreased beta cell apoptosis and increased beta cell neogensis, can
be seen (Vasavada et al., 1996).
Reg (regenerating gene) has been isolated from regenerating islets of mice undergone 90 % partial
pancreatectomy (Terazono et al., 1988). In non-regenerating pancreas Reg is expressed only in the
exocrine tissue (Miyaura et al., 1991). Receptor for Reg is expressed both in the normal pancreatic
islets as well as in regenerating islets (Kobayashi et al., 2000). Reg protein has been shown to
stimulate beta cell growth both in vitro and in vivo(Watanabe et al., 1994b). In human fetal islet cell
cultures, expression of Reg is increased during the increased beta cell replication, and decreased as
beta cell differentiation is induced (Otonkoski et al., 1994). Another islet neogenesis-associated
gene (INGAP) was isolated from cellophane wrapped hamster pancreases. INGAP (islet neogenesis
associated protein) has 40 % identity to the rat Reg protein and like Reg, it is expressed only in the
exocrine pancreas. Addition of INGAP to hamster pancreatic ductal epithelial cell culture or to rat
pancreatic duct cell line induces DNA-synthesis (Rafaeloff et al., 1997).
Glucagon-like peptide-1 (GLP-1) is cleaved from proglucagon precursor and is secreted from
intestinal enteroendocrine cells in response to oral glucose administration. GLP-1 has been shown
to lower blood glucose both in NIDDM and IDDM patients. Binding of GLP-1 to its receptor on
islet beta cells stimulates insulin secretion and increases insulin mRNA via insulin gene
transcription. GLP-1 also inhibits glucagon secretion. Exendin-4, a GLP-1 analog with long half-
life, has been shown to increase both beta cell replication and neogenesis in rats undergone partial
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pancreatectomy (Xu et al., 1999), and to exert insulinotropic effects on pancreatic exocrine AR42J
cell line (Zhou et al., 1999).
Tyrosine kinase receptor Flk-1 (receptor for VEGF) is expressed in cells lining rat fetal pancreatic
ducts and in adult rat pancreatic ducts. Vascular endothelial growth factor (VEGF) instead, is
produced by fetal and adult rat islets (Öberg et al., 1994; Rooman et al., 1997). Endothelial signals
have been shown to be essential for induction of insulin expression in the foregut endoderm.
Culture of prepancreatic (e8.5) endoderm with endothelial cells leads to pancreatic differentiation,
whereas ablation of endothelial signals prevents pancreatic differentiation in endodermal culture. In
mice expressing VEGF under the Pdx1 promoter, pancreatic islet hyperplasia ensued, further
indicating a role for endothelial factors in endocrine pancreas development (Lammert et al., 2001).
Also in vitro addition of VEGF has islet cell promoting effects in fetal pancreas (Öberg-Welsh et
al., 1997), whereas in adult rat pancreatic duct culture VEGF induces duct cell proliferation
(Rooman et al., 1997).
Trk-A, a receptor for nerve growth factor (NGF), is expressed in fetal rat pancreatic ducts. In adult
rat pancreas Trk-A is expressed in islet beta cells (Scharfmann et al., 1993), and also NGF is
produced and secreted by adult rat beta cells (Rosenbaum et al., 1998). Inhibition of Trk-A activity
in an in vitro culture system of fetal rat islets has been shown to inhibit normal islet morphogenesis
(Kanakagantenbein et al., 1995). More recently a role has been demonstrated for NGF in the
regulation of beta cell function and insulin secretion (Rosenbaum et al., 2001).
Another receptor tyrosine kinase, c-Kit, is present both in fetal and adult rat islets. In the adult
pancreas Kit is expressed in some of the beta cells, whereas in the embryonic pancreas expression is
seen in insulin positive and glucagon positive cells as well as in a specific epithelial cell population
that stained negative for endocrine markers (Rachdi et al., 2001). Pancreatic expression of stem cell
factor (SCF), the ligand for c-Kit, has not been demonstrated.
Platelet derived growth factor (PDGF) can induce proliferation of fetal rat islet cells in in vitro
culture (Swenne et al., 1988). In addition, transfection of adult pacreatic beta cells with PDGFb-
receptor also induces beta cell DNA synthesis in in vitro conditions (Welsh et al., 1990).
Retinoid receptors are expressed in the pancreatic exocrine compartment, and it has been shown
that exogenous addition of either 9-cis retinoic acid or all-trans retinoic acid to early embryonic
pancreas culture can direct pancreatic lineage selection between ductal and acinar phenotype
(Kadison et al., 2001). Culturing of human fetal pancreas with retinoic acid has also been
demonstrated to induce functional beta cell maturation (Tuch and Osgerby, 1990). Both retinoids as
well as vitamin D analogs have been shown to inhibit growth of pancreatic cancer cells (Zugmaier
et al., 1996). Vitamin D has also been demonstrated to inhibit RIN cell growth (Lee et al., 1994).
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Gastrin receptors are expressed in the rat pancreatic ductal cells, and it has been shown that gastrin
can induce pancreatic duct cell proliferation (Rooman et al., 2001). Gastrin has also been shown to
stimulate beta cell neogenesis in duct-ligated rats, where transdifferentiation of acinar tissue
towards ductal tissue occurs (Rooman et al., 2002).
3.2. Extracellular matrix, cell adhesion molecules and matrix metalloproteinases in pancreatic
morphogenesis
Differentiation of the various pancreatic cell types occurs even before the organ gets its final
morphogenetic form, characterized by well-formed islets of Langerhans scattered throughout the
exocrine tissue. In the mature islets the endocrine cells are organized in a specific way: beta cells
are in the central core of the islet surrounded by the non-beta cells. It is thought that these
differentiated islet cells, first found close to the ductal epithelium, migrate out of their epithelial
location and then reaggregate to form mature islets. Both cell surface adhesion molecules and
molecules with proteolytic characteristics are considered to have a role in these processes.
Cell-cell and cell-matrix intercations have a role both during tissue morphogenesis as well as in the
function of adult tissues. Several types of cell adhesion receptors (e.g. integrins, cadherins and
members of the Ig superfamily) are involved in aggregation and organization of endocrine cells to
form islets. Both calcium-dependent cadherin type cell adhesion molecules (CAMs) and calcium-
independent CAMs (e.g. N-CAM) are expressed both during the pancreas development (Esni et al.,
1999; Esni et al., 2001), and in the adult pancreatic islet cells (Langley et al., 1989). During
pancreas development N-cadherin is initially expressed in pancreatic mesenchyme and endoderm
and later in pancreatic islet cells. Mice deficient for N-cadherin suffered from dorsal pancreatic
agenesis. However, N-cadherin (-/-) dorsal endoderm underwent evagination, branching and
morphogenesis when cultured with wild type mesenchyme indicating that N-cadherin is essential
for the survival of the dorsal pancreatic mesenchyme (Esni et al., 2001). Also R- and E-cadherin are
expressed in the pancreas. It has been demonstrated that beta cell specific inhibition of their
function perturbs clustering of endocrine cells into islets suggesting an important role in the
regulation of adhesive properties of beta cells during the aggregation of endocrine cells into mature
islets (Dahl et al., 1996). During the early stages of pancreas development, N-CAM is expressed
both in the pancreatic mesenchyme and endoderm, later on its expression is restricted to endocrine
islet cells and nerve fibers and ganglia. In pancreatic islets all endocrine cells show membranous N-
CAM expression though this expression is much stronger in the peripheral non-beta cells than in
beta cells. Inhibition of N-CAM function in vitro prevents the segregation of beta and non-beta cells
and islets that are formed have a mixed organization of beta and non-beta cells. Furthermore, in
mice deficient for N-CAM normal localization of endocrine cells within islets is lost. N-CAM thus
seems to have a role in islet cell type segregation and organization (Cirulli et al., 1994; Esni et al.,
1999).
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The integrin family of adhesion receptors regulates interaction of cells with various extracellular
matrix (ECM) components. Integrin receptors avb3 and avb5, acting as receptors for fibronectin,
vimentin and collagen IV, are expressed in the developing human pancreas in the ductal cells and
clusters of cells branching from the ducts. Fibronectin and collagen IV are expressed in the basal
membrane of pancreatic duct cells and vitronectin in the epithelial cells adjacent to pancreatic ducts.
In differentiated islets of Langerhans the expression of both avb3 and a vb5 is downregulated.
Inhibition of avb3 and a vb5 function in the fetal islet perturbs islet cell migration from ductal
epithelium. This suggests that interaction of integrins avb3 and avb5 with their ligands has a specific
role in the regulation of human islet morphogenesis during development (Cirulli et al., 2000).
Matrix metalloproteinases (MMPs) are zinc-dependent enzymes that are involved in tissue
remodeling and extracellular matrix turnover during embryogenesis. MMPs are secreted as inactive
pro-MMPs that are activated by proteolysis (Werb, 1997). MMPs are expressed in the pancreatic
mesenchyme and could thus be involved in pancreatic epithelial invasion through the mesenchymal
tissue (Reponen et al., 1992). Also rat pancreatic islets express several MMPs and their inhibitors
(Barro et al., 1998). MMP-2 is activated from its inactive precursor form during the time when islet
morphogenesis takes place. Inhibition MMP-2 activity leads to impairment of islet morphogenesis.
TGF-b is a key activator of MMP-2 in the developing pancreas (Miralles et al., 1998). Also EGFR
ligands have been shown to upregulate MMPs (Kondapaka et al., 1997), and in mice lacking EGFR
secretion of MMPs is decreased in developing mandibles (Miettinen et al., 1999).
4. Epidermal growth factor (EGF) -family and erbB-receptors
4.1. Epidermal growth factor family and related receptors
All members of the epidermal growth factor (EGF) -family share the same basic structure: the EGF-
like domain containing six characteristically spaced cysteine residues. This sequence folds into
three disulfide-linked loops. This EGF unit is essential for ligand binding (Savage et al., 1972).
EGF-family growth factors are synthesized as membrane-anchored precursors that can be
sequentially cleaved to release soluble, bioactive ligands. Epidermal growth factor (EGF) is the first
identified member of the family. It was initially discovered by its potential to accelerate eye-
opening and tooth eruption in newborn mice (Carpenter and Cohen, 1990). Other EGF -family
growth factors are transforming growth factor -a (TGF-a) (Derynck, 1988), heparin binding EGF
(HB-EGF) (Raab and Klagsbrun, 1997), amphiregulin (Shoyab and Plowman, 1989), epiregulin
(Toyoda et al., 1997), betacellulin (Shing et al., 1993), and four neu differentiation factors (NDFs)
also called neuregulins (NRGs) or heregulins (Carraway III et al., 1997; Holmes et al., 1992;
Pinkas-Kramarski et al., 1994; Wen et al., 1992; Harari et al., 1999).
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EGF-family growth factors activate a group of four receptor tyrosine kinases encoded by the erbB
gene family (erbB1/EGF-receptor, erbB2/neu, erbB3 and erbB4) (Kraus et al., 1989; Plowman et
al., 1993; Ullrich et al., 1984; Yamamoto et al., 1986). ErbB1/EGFR binds EGF-family ligands that
share an EGF-like motif (EGF, TGF-a, amphiregulin, betacellulin, HB-EGF and epiregulin)
(Barnard et al., 1994) but betacellulin, epiregulin and HB-EGF can also bind to erbB4. Binding to
erbB4 leads to cellular responses distinct from those mediated by EGFR activation (Elenius et al.,
1997; Komurasaki et al., 1997; Riese II et al., 1996). Neuregulins were first discovered from the
search of a ligand for erbB2 (Holmes et al., 1992). NRGs however can not bind to erbB2 though
they can phosphorylate it via heterodimerization with a distinct erbB receptor. It has since been
shown that both erbB3 and erbB4 can function as receptors for NRG1 and NRG2 (Carraway III et
al., 1997; Riese II et al., 1995), whereas NRG3 and NRG4 only bind erbB4 (Harari et al., 1999;
Zhang et al., 1997) (Figure 4). Ligand for erbB2 has so far not been identified and it appears that
erbB2 is a co-receptor for other erbBs.
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erbB2/neu
erbB3
erbB4
HB-EGF
NRG1
?
TGF-a
EGF
Betacellulin
EGFR/erbB1
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Amphiregulin
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NRG4
Figure 4. Ligand binding within EGF-family. ErbB-family of receptors consists of four members. EGFR/erbB1 binds
all EGF-family ligands except neuregulins (NRGs). NRG1 and NRG2 bind to erbB3 and -4, NRG3 and NRG4 bind
only to erbB4. Betacellulin, HB-EGF and epiregulin can bind both to EGFR and erbB4. Ligand for erbB2 has not been
discovered. Ligand binding leads to phosphorylation of receptor tyrosine kinases. ErbB3 lacks the intrinsic tyrosine
kinase activity.
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Members of the erbB-family are structurally closely related. A single hydrophobic membrane
anchor sequence separates the extracellular ligand-binding domain from the cytoplasmic domain
that contains the highly conserved tyrosine kinase domain. Ligand binding to the extracellular
domain induces formation of receptor homo- or heterodimers that subsequently trigger distinct
downstream signaling cascades leading to cell differentiation or proliferation. Receptor
dimerization is a prerequisite for subsequent receptor activation. In addition, dimerization increases
the number of choices for the intracellular signaling pathways that are activated (Carraway III and
Cantley, 1994; Riese II et al., 1995; Todderud and Carpenter, 1989). Receptor dimerization is
hierarchial: erbB2 is a preferred heterodimerization partner for other erbBs (Graus-Porta et al.,
1997) and involvement of erbB2 is essential in mediation of many cellular responses. For example
no stimulation of tyrosine phosphorylation occurs in response to NRGs in cells that express erbB3
alone, but co-expression of erbB2 and -3 reconstitutes a high affinity receptor for NRG (Sliwkowski
et al., 1994). ErbB2 prolongs and amplifies signal transduction by several EGF-like ligands by
decelerating their rate of dissociation from the direct receptor.
Specificity of ligand-induced signal transduction is determined by the expression levels of specific
erbB receptor combinations (Sundaresan et al., 1998) and by the unique downstream signals
activated by each ligand (Sweeney et al., 2001). It has even been shown that different ligands for a
single receptor dimer induce different patterns of phosphorylation of intracellular signaling
molecules (Sweeney et al., 2000). Both EGFR and erbB4 can be translocated to the nucleus after
binding of their ligand, and thus may directly function as transcription factors without activation of
intracellular donwstream signaling-pathways (Lin et al., 2001; Ni et al., 2001). ErbB4 signaling
diversity is even greater, since four structurally and functionally distinct erbB4 isoforms have been
identified. These isoforms differ in their tissue distribution and in the intracellular signal
transduction pathways they activate (Elenius et al., 1999; Junttila et al., 2000).
4.2. Expression pattern and function of erbB-receptors
EGF-receptor is expressed in most tissues of the body (Adamson et al., 1981) and its over-
expression is related to epithelium-derived tumors. Other members of the erbB gene family have
initially been described by their expression in tumor tissues and they posses significant roles in
oncogenesis (Hynes and Stern, 1994). However, there is also wide distribution of these receptors in
normal tissues. ErbB2 is essential in the regulation of normal cardiac and nervous system
development and its expression in epithelial tissues and fibroblasts is broader than expression of
other erbBs (Lee et al., 1995). ErbB3 expression is detectable in a variety of normal tissues of
epithelial origin (Kraus et al., 1989). ErbB4 is expressed for example in heart, skeletal muscle,
brain, kidney and pancreas (Plowman et al., 1993). In the mammary gland, all four erbB receptors
are expressed in cell type- and developmental stage-specific patterns (Schroeder and Lee, 1998).
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The importance of erbBs in developmental processes has been obtained from mice with null
mutations for erbBs. Loss of functional EGFR leads to embryonic or perinatal lethality, and to
abnormalities in EGF-responsive organs (skin, intestine), and in organs undergoing branching
organogenesis during development (lung, kidney, mammary gland, pancreas and prostate).
Interestingly, the severity of the EGFR deficiency was dependent on the genetic background. In CF-
1 background homozygous EGFR mutation resulted in peri-implantation lethality, whereas mid-
gestation lethality was seen in 129/Sv mice, and peri- or postnatal lethality in mice with CD-1 or
C57BL/6J background (Miettinen et al., 1995; Miettinen et al., 1997; Siblia and Wagner, 1995;
Threadgill et al., 1995). Also other members of the erbB gene family appear to be essential for
normal organogenesis. Inactivation of erbB2 leads to embryonic death at e10.5 due to lack of
cardiac myocyte differentiation (Lee et al., 1995). Also erbB3 (-/-) mice show cardiac
abnormalities, and die at e13.5 due to defective heart valve formation. Another major defect in
erbB3 (-/-) embryos is seen in the midbrain/hindbrain differentiation. (Erickson et al., 1997). ErbB4
is an essential in vivo regulator of both cardiac muscle differentiation and axon guidance in the
central nervous system (CNS). Mice lacking erbB4 die during mid-embryogenesis due to
abnormalities in the development of cardiac trabeculae. There are also striking changes in the
innervation of hindbrain in the CNS (Gassmann et al., 1995).
Expression of erbB ligands is organ- and developmental stage-specific. While some erbB ligands
(e.g. NRG1 and NRG2) are expressed in several tissues of the developing embryo (Carraway III et
al., 1997; Meyer and Birchmeier, 1994), others (like NRG4) show very restricted expression
patterns (Harari et al., 1999).
Mice with null mutation for NRG1 show similar phenotypic abnormalities to erbB2 and erbB4
deficient embryos and also die at e10.5 due to cardiac trabeculae malformation (Meyer and
Birchmeier, 1995). Mice lacking TGF-a have abnormalities in their hair follicles and delayed
eyelid development (Mann et al., 1993). Similar phenotype has been discovered in spontaneous
mouse mutant waved-1, that express reduced amount of TGF-a  (Luetteke et al., 1993). In mice
deficient for EGF no overt phenotype can be observed. In mice deficient for amphiregulin ductal
growth in the mammary gland is impaired, and in mice lacking EGF, TGF-a and amphiregulin
lactogenesis is abrogated (Luetteke et al., 1999).
4.3. EGF-family and erbB-receptors in pancreas development and function
All four erbB receptors are expressed in the developing pancreas. EGFR is expressed throughout
the fetal pancreas (Miettinen and Heikinheimo, 1992), expression of other erbB receptors is
detected in primitive fetal ducts (Kritzik et al., 2000). ErbB receptor expression has also been
detected in the newborn and adult pancreatic tissues (Kritzik et al., 2000; Press et al., 1990).
Evidence for the role of erbB3 and especially EGFR in pancreas development has been obtained
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from gene inactivation studies. ErbB3 (-/-) mice die at e13.5 therefore their pancreas development
can not be studied properly. ErbB3 (-/-) embryos however have signs of attenuated pancreatic
development and reduced endocrine differentiation (Erickson et al., 1997). EGFR (-/-) mice instead
survive to term and their pancreatic phenotype was studied in the present work. There is no
information about the role of erbB2 or erbB4 inactivation in the developing pancreas because
embryos die already at e10.5, prior to pancreas organogenesis (Gassmann et al., 1995; Lee et al.,
1995).
Several erbB ligands are also widely expressed in the developing pancreas, and their over-
expression can affect pancreas growth and differentiation. In human fetal pancreas TGF-a  is
present both in exocrine and endocrine tissue. In islets it is coexpressed with insulin (Miettinen and
Heikinheimo, 1992). In mouse pancreas TGF-a overexpression has been shown to result in
hyperplasia of PDX1 positive ductular cells and progressive interstitial fibrosis. The metaplastic
ductules that were formed, contained numerous insulin expressing cells indicating islet neogenesis,
however, no increase in either acinar or islet cell mass could be detected (Jhappan et al., 1990; Song
et al., 1999). Coexpression of TGF-a and gastrin instead significantly increases islet mass in mice
expressing both transgenes (Wang et al., 1993). In addition, it has been shown that when islet
neogenesis is induced by duct ligation, expression of both TGF-a and gastrin is upregulated (Wang
et al., 1997). It has also been shown that both EGF and TGF-a are involved in the regulation of
gastrin gene expression and are weak stimulants of gastrin release (Ford et al., 1997).
Also EGF is present both in the developing (Kajikawa et al., 1991) and adult (Krakowski et al.,
1999a) pancreas, and it has been shown to induce pancreatic duct cell proliferation in several
species. Systemic EGF treatment in pigs has been shown to induce hyperplasia of interlobular
pancreatic ducts (Vinter-Jensen et al., 1997). As pancreatic rudiments from e12.5 mouse embryos
were cultured in collagen gels in the presence of exogenously added EGF, increased formation of
duct-like structures was detected (Sanvito et al., 1994). Culture of e13.5 rat isolated pancreatic
epithelium with EGF also induced proliferation of epithelial cells (Cras-Meneur et al., 2001). In
mice overexpressing EGF under the insulin promoter the islet size was increased and there was
significant fibrosis around the islets (Krakowski et al., 1999a). In isolated adult rat pancreatic islets
exogenously added EGF instead, has been shown to stimulate proinsulin biosynthesis and also
DNA content of the islets (detected by 3H-thymidine uptake) (Chattergee et al., 1986). In g-
interferon transgenic mice there is inflammation-induced islet cell loss and concomitantly continual
growth and differentiation in the pancreas. Islet cells in these mice have a unique capacity to
regenerate from proliferating ducts. Transient upregulation of EGF, TGF-a and EGFR can be
detected in these g-interferon transgenic mice in acinii undergoing differentiation into duct-like
structures (Arnush et al., 1996). Transgenic overexpression of amphiregulin instead has been shown
to induce cell proliferation in small pancreatic ducts (Wagner et al., 2002).
                     32
HB-EGF is a potent mitogen and chemotactic factor for fibroblasts, smooth muscle cells and
keratinocytes (Elenius et al., 1997). During pancreatic development HB-EGF is abundantly
expressed both in the endocrine pancreas and in the primitive duct cells from which the endocrine
cells are derived. Expression of HB-EGF is not detected in the exocrine compartment. The
expression pattern of HB-EGF in the fetal pancreas is similar to that of PDX1, suggesting that HB-
EGF may function as a mediator of PDX1, and thus be involved in the development of the
endocrine pancreas (Kaneto et al., 1997). NRG1 is also expressed in the ductal epithelial cells of the
fetal pancreas (Kritzik et al., 2000) and NRG4, a novel member of the neuregulin family, is
predominantly expressed in the pancreas (Harari et al., 1999).
Betacellulin was first identified in the conditioned medium of cell lines derived from mouse
pancreatic beta cell tumors (bTC-3 cells) (Shing et al., 1993). The mRNA for betacellulin is
detected in thymus, lung, heart, liver, spleen, small intestine, pancreas, kidney, muscle, testis and
uterus of the mouse. Expression of betacellulin is also detectable in pancreatic islets and ductal cells
from normal adult mice. It is also present in several islet tumor cells as well as in the fetal mouse
pancreas already at embryonic day 12 (Miyagawa et al., 1999; Shing et al., 1993). Betacellulin is
equipotent with EGF in stimulating fibroblast proliferation (Watanabe et al., 1994a). This growth-
promoting action of betacellulin is exerted through the EGF receptor (Watanabe et al., 1994a), and
antibodies to the EGF receptor act as betacellulin antagonists (Modjtahedi and Dean, 1996).
However, betacellulin not only stimulates tyrosine phosphorylation of EGFR, but it can also
activate erbB4 (Riese II et al., 1996). Recent data also suggest the existence of a yet unknown
receptor for betacellulin. In a pancreatic exocrine cell line, AR42J, apart from erbB1, betacellulin
also binds to a protein different from the erbB proteins. This protein is tyrosine phosphorylated after
binding betacellulin and its molecular weight is approximately 190 kDa. (Ishiyama et al., 1998).
Betacellulin has been shown to exert mitogenic activities in many cell types. It stimulates
proliferation of retinal pigment epithelial cells and vascular smooth muscle cells (Shing et al., 1993)
as well as undifferentiated human fetal pancreatic epithelial cells (Demeterco et al., 2000). On the
other hand, betacellulin also has differentiation inducing effects. Activin A and betacellulin can
together convert exocrine AR42J cells into neuron-like cells expressing both insulin and pancreatic
polypeptide (PP) (Mashima et al., 1996a) and in 90% pancreatectomized rats addition of
betacellulin accelerates beta cell regeneration (Li et al., 2001).
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5. Fibroblast growth factor (FGF) -family and FGF-receptors
5.1. Fibroblast growth factor (FGF) -family and related receptors
Fibroblast growth factors (FGFs) make up a family of at least 22 polypeptide growth factors in
vertebrates. The 22 known FGFs have a molecular mass ranging from 17 to 34 kDa and share 13-71
% amino acid identity. Common feature of the FGF-family members is a strong affinity for heparin,
and heparan-like glycosaminoglycans (HLGAGs), which are required for the binding of FGFs to
their high affinity cell surface receptors. Most of the FGFs contain a signal sequence for secretion
via classical secretory pathway, FGFs 1, 2, 9, 16 and 20 lack this leader sequence but FGFs 9, 16
and 20 are still secreted. FGFs are important regulators of embryonic development, but they also act
in wound healing and are potent angiogenic factors. First members of the FGF-family (FGF1/acidic
FGF and FGF2/basic FGF) were isolated from bovine pituitary extracts on the basis of their
mitogenic activity on fibroblasts (Armelin, 1973; Gospodarowicz, 1974), also several other FGFs
have fibroblast stimulating activities (Ornitz and Itoh, 2001; Powers et al., 2000).
FGFs signal through four cell-surface tyrosine kinase receptors (FGFR1, -2, -3 and -4) and induce
receptor dimerization. This dimerization is facilitated by HLGAGs. FGF-receptors share 55 to 72 %
homology at the protein level and are characterized by three extracellular immunoglobulin (Ig)-like
domains, an acidic region between IgI and IgII, a transmembrane domain, and an intracellular
tyrosine kinase domain. Both second and third Ig-loops are involved in ligand binding. Third of the
extracellular Ig-like loops (IgIII) is spliced alternatively in FGFR1, -2 and -3 to form different
receptor isoforms (Figure 5). Differential splicing may also result in the loss of IgI, which however,
does not alter the binding capacity of the receptor. The FGFR4 gene has only one possible form.
The IgIIIa receptor splice variant codes a truncated protein that does not contain the transmembrane
part and thus can not act in signal transduction. IgIIIb and IgIIIc are expressed differentially and
also have different ligand-binding specificities and thus mediate specific actions of different FGFs
(Ornitz et al., 1996; Orr-Urtreger et al., 1993; Powers et al., 2000).
Figure 5. Alternative splicing of FGF-receptors (Modified from De Moerlooze et al., 2000)
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5.2. Expression pattern and function of FGF-receptors
FGFR variants are expressed in different locations during the development and thus seem to have
unique roles in signal transduction. Both FGFR1 and FGFR2 are detected in the primitive ectoderm
of the postimplantation embryo. Later during development the expression patterns of FGFRs 1, 2,
and 3 are distinct and expression of either IIIb or IIIc splice variant is dependent upon cell lineage
so that IIIb exon is predominantly expressed in epithelial tissues whereas IIIc is located primarily in
the mesenchyme. In addition to variable tissue distribution of different FGFRs, they also vary in
their ligand specificity so that some ligands preferably bind to IIIb isoforms, whereas others show
activity toward IIIc isoforms. FGF1 is the only ligand that binds to all FGF receptor splice variants
as well as to FGFR4 (Ornitz et al., 1996; Orr-Urtreger et al., 1993; Powers et al., 2000).
FGFs and their receptors have a central role in development. FGF signaling is involved in cell
division of the mouse embryo even prior to implantation (Chai et al., 1998). FGFs are also involved
in the formation of the three germ layers during gastrulation. FGFs also have crucial roles for
example in the development of the nervous system (Crossley et al., 1996), the lung (Sekine et al.,
1999), and most prominently in the development of the limb (Martin, 1998). Mutations in FGFRs
are associated with heritable autosomal dominant skeletal disorders in human (De Moerlooze and
Dickson, 1997). In mouse, attempts to study specific organ development after inactivation of
individual FGFs or both isoforms of a specific FGFR have often failed due to early embryonic
lethality. Mice deficient for both isoforms of FGFR1 die during gastrulation and display severe
growth retardation and defective mesoderm patterning (Deng et al., 1994; Yamaguchi et al., 1994).
Embryos lacking IIIc isoform of the FGFR1 resemble embryos deficient for both isoforms of the
FGFR. Mice lacking FGFR1b are viable and show no apparent phenotype, indicating that IIIc is the
dominant FGFR1 isoform (Partanen et al., 1998). Mice lacking both isoforms of FGFR2 die at e4.5
- 5.5, soon after implantation (Arman et al., 1998). Also null mutations of FGF4 (Feldman et al.,
1995) and FGF8 (Sun et al., 1999) lead to early embryonic lethality prior to organ induction. On the
other hand, due to functional redundancy within FGF- and FGFR-families, mutations in a single
FGF gene can also yield to little or no apparent phenotype. For example mice lacking FGFR4
(Weinstein et al., 1998) have no apparent embryonic phenotype. Loss of FGF5 and FGF7 results in
abnormal hair growth (Guo et al., 1996; Hebert et al., 1994), whereas FGF3 deficient mice have
perturbed ear development (Mansour, 1994). FGFR3 deficient mice have problems with long bone
and inner ear development (Colvin et al., 1996).
The IIIb isoform of FGFR2 (FGFR2b) has been demonstrated as an important regulator of
vertebrate organogenesis. Its role in mouse development has more specifically been studied using
FGFR2b dominant-negative receptors (Celli et al., 1998; Peters et al., 1994), and by deleting the
exon encoding FGFR2b (De Moerlooze et al., 2000). Inactivation of FGFR2b leads to death of
fetuses at birth due to agenesis of lungs. Both mice carrying a dominant-negative mutation for
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FGFR2b as well as FGFR2b deficient mice have a failure in the development of limbs, abnormally
curled tail and open eyes. Anterior pituitary is absent and this is associated with craniofacial
abnormalities, such as cleft palate, abnormal tooth development and reduced otic capsules. There
are defects also in the development of the salivary gland, mammary gland (Mailleux et al., 2002),
inner ear (Pirvola et al., 2000) and skin.
FGF10 is considered to be the major ligand for FGFR2b, and it is usually expressed in the
mesenchyme surrounding the developing FGFR2b positive epithelia (Ohuchi et al., 2000). For
example in the developing lung, FGF10 is expressed in the mesenchyme in close vicinity of
developing lung buds. FGF10 was initially discovered because it is a homologue of FGF7 (Igarashi
et al., 1998). However, whilst FGF7 only binds to and activates FGFR2b, FGF10 can in addition
bind to FGFR1b (Figure 6) (Lu et al., 1999). The phenotype of mice lacking FGF10 seems to be
quite similar to FGFR2b (-/-) phenotype. FGF10 (-/-) fetuses survive to birth, but then also die due
to lack of lungs. Another characteristic feature in FGF10 mutants is the absence of limbs. In
addition FGF10 (-/-) fetuses like FGFR2b mutants lack
anterior pituitary and salivary glands. They also have
defects in the development of teeth, inner ear, kidney, hair
follicles, thymus, mammary gland and pancreas (Bhushan
et al., 2001; Mailleux et al., 2002; Min et al., 1998; Ohuchi
et al., 2000; Sekine et al., 1999). Unlike FGF10 mutants,
mice deficient for FGF7 are viable, and only abnormalities
detected in FGF7 mutants is their rough hair and slightly
disturbed ureteric bud growth (Guo et al., 1996; Qiao et al.,
1999).
5.3. FGFs in pancreas development and function
FGFs and their receptors have been implicated during embryonic pancreas development as well as
in the function of adult beta cells. Some studies point out a role for FGFs in the regulation of early
endoderm differentiation as well as in the initial stages of pancreas development. FGF4 is expressed
in primitive-streak mesoderm and it has been shown to induce posterior endodermal markers (Wells
and Melton, 2000). One of the signaling factors expressed in the notochord during pancreas
specification is FGF2, which induces Pdx1 expression in endodermal in vitro culture (Hebrok et al.,
1998). More recently, it was also demonstrated that FGFs secreted by early cardiac mesoderm
induce hepatic markers while repressing pancreatic markers (Deutsch et al., 2001).
Figure 6. FGF7 binds only to FGFR2b
whereas FGF10 can also bind to FGFR1b
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Expression of FGFR1, FGFR4, FGFR2b and some FGF ligands has previously been demonstrated
in the developing rodent pancreas (Arany and Hill, 2000; Le Bras et al., 1998; Miralles et al., 1999).
Expression of the IIIc isoform of FGFR1 has been shown both in epithelial and mesenchymal cells
of fetal rat pancreas, whereas expression of FGFR1b is seen only in the epithelial fraction (Cras-
Méneur and Scharfmann, 2002). Expansion of pancreatic epithelial endocrine precursor cells with
relevant growth factors also induced expression of FGFR1b, indicating that it might be a marker for
pancreatic progenitor cells (Cras-Méneur and Scharfmann, 2002). FGFR1 expression has also been
shown in adult mouse beta cells as well as in the exocrine tissue (Hart et al., 2000). Also FGFR2
expression is detected in the developing rodent pancreas (Miralles et al., 1999) and in the adult
mouse pancreatic beta cells (Hart et al., 2000). IIIb isoform of FGFR2 is expressed in the epithelial
compartment of the developing mouse pancreas, whereas expression of FGFR2c is seen in the
embryonic pancreatic mesenchyme (Elghazi et al., 2002). Expression of FGFR4 has been detected
in the epithelial part of rat embryonic pancreas (Öberg-Welsh and Welsh, 1996; Elghazi et al.,
2002; Le Bras et al., 1998), whereas in the adult rat pancreas its expression is undetectable (Le Bras
et al., 1998). Recently, cDNA endoding novel protein that is highly homologous to known FGFRs
was isolated. This novel protein was nominated fibroblast growth factor receptor 5, and its
expression was abundant in the pancreas. FGFR5 was demonstrated to bind FGF2, but it lacks the
tyrosine kinase domain (Sleeman et al., 2001; Kim et al., 2001).
Some FGF ligands are also expressed in the developing rodent pancreas. Expression of FGF10 is
detected in the mesenchyme surrounding the epithelial pancreatic buds from e9.5 to e11.5.
(Bhushan et al., 2001). FGF7 expression becomes detectable in late embryonic pancreas (Miralles
et al., 1999). FGF1, FGF7 and FGF10 as well as FGF2, FGF4 and FGF5 have all been detected in
adult mouse beta cells (Hart et al., 2000).
Exogenous FGF1 has been shown to induce epithelial growth and differentiation of exocrine cells
in epithelial cultures from e11.5 rat pancreas (Miralles et al., 1999). Also FGF2 has been shown to
induce proliferation of epithelial cells prepared from e13 rat pancreas (Le Bras et al., 1998). In
e11.5 rat epithelial pancreatic culture FGF7 and FGF10 induce both epithelial growth as well as
exocrine differentiation. An in vitro increase in the proliferation of pancreatic endocrine progenitor
cells but a decrease in the number of differentiated endocrine cells by exogenous addition FGF7 has
also been demonstrated (Elghazi et al., 2002). FGF7 also induces duct cell proliferation in the adult
rat pancreas. (Krakowski et al., 1999b; Yi et al., 1994). Overexpression of FGF7 in beta cells
resulted in disorganized islet growth and emergence of hepatocytes within islets (Krakowski et al.,
1999a; Krakowski et al., 1999b). Transgenic expression of FGF8 under the glucagon promoter
induced hepatocyte differentiation in the peripheral part of pancreatic islets. Overexpression of
FGF10 in similar experiments induced appearance of both ductal and acinar cells within the islets
and disruption of normal beta cell development (Yamaoka et al., 2002).
Further evidence for the role of FGF-mediated signaling in pancreas development and function has
been obtained from gene inactivation studies. The pancreas of mice expressing a soluble dominant-
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negative form of FGFR2b appeared hypoplastic (Celli et al., 1998). Furthermore, e11.5 rat
pancreatic rudiments cultured with antisense oligonucleotides to FGFR2b resulted in a reduced
DNA content and reduced number of amylase producing cells (Miralles et al., 1999). In mice
expressing a dominant-negative FGFR2b construct under the Pdx1 promoter, pancreas development
and function, however, are normal. In mice deficient for FGF10 (the major ligand for FGFR2b)
pancreas is hypoplastic and lacks branched structures. In FGF10 null mice severe reduction in the
number and proliferation of PDX1-positive pancreatic epithelial progenitor cells is evident from
e10.5 onwards. Subsequently, a marked reduction in the number of islet cells expressing insulin can
be seen (Bhushan et al., 2001). In mice deficient for FGF7 (another ligand for FGFR2b), instead, no
obvious pancreatic phenotype can be seen (Guo et al., 1996). This is in agreement with the
observations that FGF7 in the developing pancreas is not detected until late in gestation (Miralles et
al., 1999), whereas FGF10 is expressed from the initial stages of pancreas development (Bhushan et
al., 2001). Mice overexpressing FGF10 under the Pdx1 promoter have increased proliferation of
pancreatic epithelium and subsequently hyperplasia of the pancreas (Hart et al., 2001). However, as
is the case in FGF10 deficient mice (Bhushan et al., 2001), the numbers of differentiated endocrine
cells are also reduced in the Pdx1-FGF10 mice (Hart et al., 2001).
The IIIc isoform of FGFR1 has been shown to be essential for proper beta cell function in the adult
mouse. Mice expressing a dominant-negative FGFR1c construct under the Pdx1 promoter become
diabetic by the age of 10 weeks. There is an atypical islet organization and 25% decrease in beta
cell number, but no increase in beta cell apoptosis. Expression of several functionally important
beta cell genes, such as GLUT-2 and PC1/3, is also downregulated (Hart et al., 2000).
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AIMS OF THE STUDY
1. To screen for possible beta cell growth and/or differentiation factors (I).
2. To study the role of epidermal growth factor (EGF) -family peptides and receptors in pancreas
growth and development (II, III).
3. To study the role of fibroblast growth factor receptor 2IIIb and its ligands in pancreas growth
and development (IV).
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GENERAL METHODOLOGY
Detailed description of used methodology can be found in the original publications.
Materials (I-IV)
Recombinant human IGF-I, bFGF, PDGF AA, PDGF BB, EGF and natural human TGFb were
obtained from Upstate Biotechnology. Recombinant human IGF-II, VEGF, betacellulin, TGF-a,
HB-EGF, FGF7, FGF10 and anti-human betacellulin antibody were obtained from R&D systems.
Recombinant human NGF-b, all-trans-retinoic acid, nicotinamide, and sodium butyrate were
obtained from Sigma. Recombinant human activin A and porcine PRL were obtained through the
National Hormone and Pituitary Program (NIH). 1,25-dihydroxyvitamin D3 was a product of Leo
Pharmaceutical Products. Recombinant human GH (Genotropin) was from Pharmacia AB.
Recombinant human HGF was a gift from Dr. Jeffrey Rubin (National Cancer Institute, Bethesda,
USA). Recombinant human NDF was a gift from Dr. Walter Birchmaier (Max Delbrück Centrum,
Berlin, Germany). Non-specific goat IgG was provided by Dr. Ilkka Seppälä (Haartman Institute,
University of Helsinki, Finland). NRG4 was synthesized as described (Harari et al., 1999). NRG4
inhibitory antibody was generated by injecting New Zealand White rabbits five times with a
purified, refolded synthetic peptide comprising the EGF-domain of NRG4 (Harari et al., 1999), with
antigenicity boostered by standard Freund’s adjuvant protocol. IgB4, a fusion protein between the
extracellular ligand binding portion of erbB4 and the Fc portion of human immunoglobulin G was
synthesized as described (Chen et al., 1996).
Cell culture studies (I)
INS-1 and RINm5F cell lines were provided by Dr. Claes Wollheim (University of Geneva,
Switzerland). Cells were cultured in tissue culture flasks at 37°C under a humified condition of 95%
air and 5% CO2 in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 mM Hepes, 100
U/ml penicillin, 100 mg/ml streptomycin and 10 % FCS. For INS-1 cell cultures 1 mM sodium
butyrate and 50 mM 2-merchaptoethanol was added to the medium. For assays the cells were
detached by a brief incubation with trypsin/EDTA. For proliferation studies, the cells were plated in
96-well plates and allowed to attach for 24 hours. For the following 24 hours the cells were
incubated in the medium containing only 0.5% FCS. For the final 24 hours incubation the studied
growth factor was added to the medium. For the measurement of DNA synthesis 1 mCi/ml of 3H-
thymidine was added to the cells for the final 4 hours. The cells were then harvested and transferred
on glass fiber filters and 3H radioactivity was measured in a liquid scintillation counter.
Alternatively, the cells were plated in 12-well plates and incubated for 4 or 7 days with complete
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medium containing the studied growth factor. Cell numbers were then counted in a hemocytometer.
For detection of insulin content, the cells were plated in 12-well plates and allowed to attach in
complete medium for 24 hours and then the studied growth factor was added to the medium for 7
days. The cells were then detached and homogenized by sonication. Cellular insulin content was
measured by radio-immuno-assay in dilutions of acid ethanol extracts. Cellular DNA content was
measured fluorometrically (Hinegardner, 1971).
Generation and genotyping of the EGFR (-/-) mice (II, III)
EGFR was disrupted as described previously (Miettinen et al., 1995). Embryos and newborn pups
used in this study derived from intercrosses between EGFR (+/-) mice. Plug-date was considered as
e0.5. E12.5 - 15.5 embryos were genotyped by PCR and Southern blot analysis as described
previously (Miettinen et al., 1995), while older EGFR (-/-) embryos could be recognized from their
open-eye phenotype. For histological analysis newborn mice plus embryos at e12.5, 13.5, 14.5, 15.5
and 16.5 were collected. For pancreatic organ cultures e12.5 embryos were collected. For cell
proliferation experiments, pregnant animals or pups were injected intraperitoneally with
bromodeoxyuridine (BrdU; 100 mg/g animal mass; Sigma) 2 hours before killing the animals.
Generation and genotyping of the FGFR2b (-/-) mice (IV)
The targeted disruption of FGFR2b, and the genotyping of offsprings by PCR analysis of genomic
yolk sac DNA has been described previously (De Moerlooze et al., 2000). Mutant embryos could be
recognized from their limb-lacking phenotype. Mutant and wild type littermates were collected at
e12.5, 13.5, 14.5, 15.5 and 18.5 for histological and in situ analysis, at e15.5 for RNA analysis, and
at e12.5 for pancreatic organ cultures.
Blood glucose levels (II)
Random blood glucose recordings were obtained from newborn animals at the time they were killed
using a portable glucose meter (MediSense Inc., Waltham, USA).
Pancreatic organ cultures (II, III, IV)
Pancreatic explant cultures from wild type, EGFR deficient and FGFR2b deficient e12.5 embryos
were used to study the in vitro development of the pancreas. The duodenal loop along with the
pancreatic rudiment and stomach were microdissected. The tissues were then cultured by a
technique originally designed for embryonic kidney (Saxen and Lehtonen, 1987). Tissue explants
consisting of dorsal and ventral pancreatic buds (mesenchyme plus epithelium), stomach and
duodenal loop, were placed on Nucleopore filters (1.0 mm pore size, Costar) on metal grids and
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cultured at the air-liquid interphase in serum-free I-MEM (Improved Eagle´s Minimum Essential
Medium, Gibco) supplemented with transferrin (30 mg/ml), penicillin (100 IU/ml) and streptomycin
(100 mg/ml) and either EGF (20 ng/ml), TGF-a (20 ng/ml), HB-EGF (20 ng/ml), betacellulin (20
ng/ml), NRG4 (1 ng/ml), anti-human betacellulin antibody (1 mg/ml), anti NRG-4 antibody (1:100),
IgB4 (10 mg/ml), non-specific goat IgG (10 mg/ml), FGF7 (50 ng/ml), FGF10 (50 ng/ml), or
cultured in plain medium (knock out embryos and control group). The media were changed every
second day. After one or five days in culture, explants were fixed for 4 hours at room temperature
(RT) in Bouin´s fixative. After rinsing with 50% alcohol, tissues were stored in 70% alcohol prior
to dehydration and paraffin embedding.
Histological analysis (II, IV)
Samples were fixed either in 4% paraformaldehyde or Bouin's fixative and processed into serial
paraffin sections using routine procedures. For general morphology, deparaffinized sections were
stained with hematoxylin. The sections were then examined under light microscope, photographed
or morphometrically analyzed directly under light microscope. E15.5 pancreases were used for the
analysis of ductal branching. For this purpose whole pancreases were sectioned through and the
number of ductal lumens was counted under the light microscope from every 20th section (6-8
sections/each pancreas) using a 10 mm grid. Number of ductal openings/mm2 was then calculated.
Immunohistochemistry (II, III, IV)
For quantitative morphometric analysis of pancreatic cell types, an entire tissue block was sectioned
for immunohistochemical stainings. Every fifth or seventh consecutive section was stained with the
same primary antibody. Deparaffinized, rehydrated sections were incubated for 2 hours at RT in 3%
normal goat or rabbit serum (Zymed, South San Francisco, CA) in PBS (pH 7.4) or for 10 minutes
in Ultra Vision blocking reagent (Lab Vision, Fremont, CA) to block nonspecific binding sites.
Sections were incubated either overnight at +4 °C or for one hour at RT with primary antibody,
diluted in PBS containing 3% normal serum (mouse anti-human E-cadherin, Transduction
Laboratories; guinea pig anti-porcine insulin, rabbit anti-human glucagon, rabbit anti-human
somatostatin, rabbit anti-human pancreatic polypeptide, DAKO; rabbit anti-human amylase,
monoclonal anti-pan cytokeratin (mixture); Sigma). All antisera were pretested for optimal dilutions
and staining conditions. After rinsing several times with PBS, sections were incubated with
biotinylated-goat anti-rabbit (ready-to-use, Lab Vision) or biotinylated-goat anti-mouse (ready-to-
use, Lab Vision) for 20 minutes at RT, rinsed and incubated with streptavidin peroxidase (ready-to-
use, Lab Vision) for 10 minutes at RT. The sections were finally developed with AEC substrate
(Lab Vision). Alternatively, after rinsing off the primary antibody the sections were incubated for
30 minutes with biotinylated-goat anti-rabbit IgG (biotinylated-rabbit anti-mouse IgG for CK)
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(Zymed), diluted in PBS, rinsed and incubated with peroxidase conjugated streptavidin (ZYMED),
diluted in PBS for 30 min at RT. The sections were developed with 3-amino-9-ethyl-carbazole
(AEC) substrate and rinsed with distilled water. Light counter-staining was performed with
hematoxylin. For simultaneous detection of insulin-, glucagon- and cytokeratin-positive cells or
insulin- and E-cadherin-positive cells, fluorochrome (FITC, TRITC and AMCA)-conjugated
secondary antibodies (Jackson Immunolaboratories) were used.
Cell proliferation was quantified by staining with Ki67 nuclear antigen or with anti-BrdU antibody
(BrdU labeled pups and embryos). For double staining of hormone plus Ki67/BrdU, the staining
protocol was continued from the one described above. The slides were treated with 10 mM citrate
buffer (pH 6.0) for 25 minutes in a microwave oven (for Ki67 staining) or with 0.1% pepsin in 0.1
M HCl at RT for 30 minutes (for BrdU staining) to reveal antigenic sites and rinsed in PBS. Double
staining was performed using the Vectastain ABC-kit (Vector, Burlingame, CA). The sections were
incubated for 1 hour at RT in 3% goat or horse blocking serum in PBS (pH 7.4) and incubated with
rabbit polyclonal Ki67 antibody (NovoCastra, Newcastle, UK), diluted 1:500 in PBS containing 3%
goat serum or with mouse monoclonal anti-BrdU antibody diluted 1:100 in 3% horse serum. After
rinsing with PBS, sections were incubated for 30 minutes with biotinylated antibody, rinsed,
incubated for 30 min in Vectastain ABC-alkaline phosphatase reagent, rinsed, and developed with
AP substrate (Vector Blue®). After color development, slides were rinsed in distilled water and
mounted with Aquamount.
After the immunohistochemical stainings the numbers of positively stained cells was either counted
manually under the light microscope or the slides were included in the computerized image analysis
using KS400 Image Analysis software.
Detection of apoptosis (II)
For detection of apoptosis deparaffinized sections were stained using the terminal
dideoxynucleotidetransferase (Tdt)-mediated ddUTP nick end labelling (TUNEL) procedure. The
sections were permeabilized by microwave treatment in 10 mM citric acid, followed by
preincubation in 5 mM CoCl2 Tdt buffer for 10 minutes and the digoxigenin-conjugated ddUTP
labeling of the nicked DNA ends by Tdt  (5 mM CoCl2, 5 mM Tdt-Buffer, 0.23 mM ddATP, 0.13
mM dig-ddUTP, 0.58 U/ml Tdt) at 37˚C for 60 minutes. To detect the labeled cells, the sections
were treated with 2 % blocking reagent (Boehringer Mannheim) in 150 mM NaCl, 100 mM Tris-
HCl buffer (pH 7.5) and treated with anti-digoxigenin Fab fragments (0.19 U/ml in blocking buffer)
at 37˚C for 60 minutes. Finally, the reaction products were visualized by incubation with a
peroxidase dye, NBT/BCIP, in 67 % DMSO, for up to 60 minutes. Nuclei were counter-stained
with hematoxylin.  Similar procedure without the Tdt-treatment was used as a negative control for
every sample. Cell specificity of apoptosis was attained by insulin immunocytochemistry following
TUNEL-staining.
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To detect DNA fragmentation at tissue level DNA was purified from neonatal pancreases using a
commercial kit (Apoptotic DNA ladder kit, Boehringer Mannheim). The purified DNA samples
were nick-end labeled with digoxigenin-ddUTP. Gel electrophoresis was performed and the DNA
blotted onto a Hybond N+ membrane. The membrane was then incubated with an anti-digoxigenin-
alkaline phosphatase antibody and further with CSPD, a chemiluminescent substrate for alkaline
phosphatase.
RNA extraction (I, II, III, IV) and analysis (I, II, IV)
Total RNA was prepared by guanidinium thiocyanate extraction followed by CsCl gradient
centrifugation (Sambrook et al., 1989) or by using GenElute total RNA isolation kit (Sigma).
mRNA was purified from total RNA preparations with oligo(T)-coated magnetic microbeads
(Dynabeads, Dynal A.S.).
Total RNA (approximately 10 mg/lane) or mRNA (1.2 mg/lane) was fractionated on a 1.2 %
formaline-agarose gel and transferred to a nylon membrane (Hybond-N, Amersham) by capillary
blotting. The cDNA probes were 32P-labeled by a random priming method (Prime-A-Gene Labeling
System, Promega). Following probes were used: Mouse EGFR cDNA and rat erbB-2 cDNA
corresponded to the extracellular domains of the receptors. Human erbB-3, erbB-4 cDNAs and
mouse 72-kDa type IV collagenase (Reponen et al., 1992) cDNAs represented the whole coding
areas of corresponding mRNAs. cDNA clones used for probe generation in work number IV were
provided by following investigators: Dr. Helena Edlund, Umeå, Sweden (mouse Ngn-3); Dr. Ole
Madsen, Gentofte, Denmark (rat Nkx6.1); Dr. Peter Wellauer, Lausanne, Switzerland (mouse p48).
Hybridizations were done in buffer containing 1% SDS, 1M NaCl, and 8% dextran sulfate
overnight at 65°C.  The blots were washed at 65°C in 1 x SSC and finally in 0.5 x SSC.
Hybridization signals were visualized using a Bio-imaging analyzer (Fuji Photo Film Co., Ltd). The
hybridization signals were normalized against the housekeeping gene cyclophilin (Bergsma et al.,
1991) or b-actin.
Reverse transcriptase (RT) PCR and primers (III)
Prior to reverse transcription RNA samples were DNase-I treated for 50 minutes at +37°C.
Thereafter the samples were phenol/chloroform extracted and precipitated after addition of 1
volume of 7.5 M NH4OAc and 2.5 volumes of ethanol. Total RNA was precipitated by
centrifugation and washed once with 75% EtOH. After precipitation with ethanol the samples were
dissolved in RNase-free water. Total RNA (2 mg) was then reverse transcribed at +37°C for 90 min.
The reaction was inactivated at 95°C for 5 min. One ml of RT reaction mixture was used for PCR
amplification. The PCR samples were heated to 95°C for 5 minutes to activate the polymerase and
then cycled for 35 times: denaturation 45 sec at 94°C, annealing 45 sec at 58°C - 63°C, elongation
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45 sec at 72°C on GenAmp PCR System 9600 apparatus. The PCR samples were electrophoresed
through 1,5 % agarose gel and visualized with ethidium bromide staining.
Following primers were used:
Rat GAPDH (5´-GTC TTC ACC ACC ATG GAG AAG GCT´& 5´-TGT AGC CCA GGA TGC
CCT TTA GTG´; EMBL/Genbank M17701, position 325-854, fragment size 530)
Mouse EGF (5´TTG AAA TGG CCA ATC TGG ATG G´ & 5´TGA CAC CAT GAT TTC AGC
CAC T; EMBL/Genbank J00380, position 2368-2855, fragment size 488 bp)
Mouse TGF-a (5´GTT CTC AGG TCC AGC CAG TC & 5´GGT TCT CTC CTT CCA CCA
GAT´; EMBL/Genbank U65016, position 2685-3225, fragment size 541 bp)
Mouse HB-EGF (5´TCT GGA GCG GCT TCG GAG AG´ & 5´CAC GCC CAA CTT CAT TTC
TC´; 5´primer exon 2 EMBL/Genbank L36024 and 3´primer exon 5 EMBL/Genbank L36027
corresponding to human HB-EGF cDNA EMBL/Genbank M60278, position 336-873, fragment
size 538 bp)
Mouse betacellulin (5´CAC AGC ACA GTT GAT GGA CC´ & 5´CCG TTA AGC AAT ATT
GGT CTC 3´; EMBL/Genbank L08394, position 100-649, fragment size 550 bp)
Mouse NRG4 (5´CTC ACT CTT ACC ATC GCG GC´ & 5´CAG CCT TAT CTA TAC TGC TGA
C´, position 328-710, fragment size 383 bp, (Harari et al., 1999))
In situ hybridization, whole mount in situ and probes (IV)
In situ hybridization was performed on deparaffinized tissue sections essentially as described
previously (Kettunen et al., 1998). The sections were hybridized with 106 cpm of [35S]-labeled
antisense riboprobes, prepared using the following murine cDNA templates: Pdx1 p48, Ngn3, Pax6,
FGFR2b, FGFR2c and rat Islet 1. Whole mount in situ hybridization was performed as described
(Revest et al., 2001). Digoxigenin-labeled mouse Pdx1 cDNA was used for the hybridization. The
cDNA clones used for the generation of probes were provided by following investigators: Dr. Päivi
Kettunen, Helsinki, Finland (mouse FGFR2c); Dr. Helena Edlund, Umeå, Sweden (mouse Ngn-3);
Dr. Ole Madsen, Gentofte, Denmark (rat Nkx6.1); Dr. Peter Wellauer, Lausanne, Switzerland
(mouse p48); Dr. Chris Wright, Nashville, TN, USA (mouse Pdx1); Dr. Peter Gruss, Göttingen,
Germany (mouse Pax6) and Dr. Samuel Pfaff, La Jolla, USA (rat Islet 1). FGFR2b cDNA was
generated as described (De Moerlooze et al., 2000).
Gelatin zymography, zymographic and reverse zymographic assays (II)
Analyses for gelatinase activity (Chin and Werb, 1997) and caseinolysis-in-agarose assays (Saksela,
1981) were carried out as described. Tissues were dissected and digested with collagenase (4 mg/ml
in Hanks buffer) in a shaking water bath (37°C for 5 minutes). Tissues were then cultured in RPMI
1640 supplemented with 10 % FCS, 10 mM Hepes, 100 U/ml penicillin, 100 µg/ml streptomycin
and 2 mM L-glutamine for 3 days. Samples of conditioned medium were collected and diluted in
non-reducing 2 x Laemmli sample buffer. Equal amounts of protein were subjected to SDS-PAGE
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under non-reducing conditions. For gelatin zymography assays the gels were washed twice after
electrophoresis with 50 mM Tris-HCl buffer (pH 7.6) containing 5 mM CaCl2, 1 µM ZnCl2 and
2.5% Triton X-100 to remove SDS. This was followed by brief rinsing in washing buffer without
Triton X-100 and then incubation in substrate buffer (50 mM Tris-HCl buffer (pH 7.6) containing 5
mM CaCl2, 1 µM ZnCl2, 1 % Triton X-100 and 0.02 % NaN3) for overnight at 37°C.  The gels were
then stained with Coomassie brilliant blue, destained with 10 % acetic acid and 10 % methanol,
dried and photographed.  Zymograms were then densitometrically scanned and the gelatinolytic
bands were quantified by NIH Image-analysis software. Conditioned medium from human
fibrosarcoma HT-1080 cells containing gelatinases A and B was used as mobility markers. For
caseinolysis assays the gels were washed with 2.5 % triton-X in PBS and then placed on
caseinolysis gels that contained 1 U plasminogen (Cromogenix), casein (1.5% milk powder) and
1.2% agarose (LITEX) in 0.1 M Tris-HCl buffer (pH 8.0) and incubated at 37°C until lysis zones
were observed. The positions of plasminogen activators (tPA and uPA) in SDS gels were
determined as lysis zones in the indicator zymography gels. To analyze the levels of plasminogen
activator inhibitor-1 (PAI-1), the SDS was removed by washing with 2.5 % Triton X-100 in PBS,
and human uPA (2 U/ml) was added for the last 30 minutes rinse. uPA induces plasminogen-
mediated digestion of  the casein, except at the zones containing PAIs, which can be seen as lysis-
resistant bands on caseinolysis gels.
NRG4 antibody and betacellulin neutralizing antibody binding (III)
To test specificity of the NRG4 antibody, NRG4 and EGF (as negative control) were both
radiolabeled with 125I (2 x 106 cpm/ml) using Iodogen (Pierce), and cleaned on a G25 Sepharose
column. 10 ml of NRG4 antisera from two independently injected rabbits were pre-adsorbed to
protein-A sepharose beads in HNTG buffer at +4°C for 30 minutes. Beads were washed three times
in HNTG buffer, blocked in HNTG + 0.1 % BSA for 30 minutes at +4°C, spinned, and incubated
for a further 2 hours with 5 ml of radio-labeled ligand at +4°C. The same protocol was repeated for
control antibodies and soluble Fc-conjugated erbB1. Beads were then washed four times with
HNTG, before being boiled in reducing sample buffer, proteins resolved by SDS-PAGE and bound
ligand detected by autoradiography. Ability of anti-human betacellulin antibody to inhibit
betacellulin activity was studied using A431 cell line (ATCC, no: CRL-1555) (Giard et al., 1973).
For this purpose cells were plated in 6-well plates and allowed to attach in D-MEM (Gibco)
supplemented with 10 % FCS, 100 IU/ml penicillin, 100 mg/ml streptomycin and 2 mM L-
glutamine for 24 hours. Cells were then serum-starved for overnight, incubated for 5 minutes at
37°C with betacellulin, anti-human betacellulin or without additions (control group). Betacellulin
was then added to cells treated with anti-human betacellulin antibody for another 5 minutes
incubation. Cells were then lysed in ice cold lysis buffer (25 mM Hepes, 5 mM EDTA, 150 mM
NaCl, 1% Triton X-100, leupeptin 20 mg/ml, aprotinin 20 mg/ml, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 0.1 mM Na-orthovanadate) and left on ice for 10 minutes. The whole cell extract
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was then cleared by centrifugation, boiled in reducing gel sample buffer, and resolved by 10 %
SDS-PAGE before transfer onto nitrocellulose filters. Filters were blocked for overnight at +4°C in
TBST buffer (10 mM TrisHCl (pH 8), 150 mM NaCl, 0.1% Tween 20) containing 5 % milk. The
filters were then blotted with anti EGFR [pY1086] phosphospecific antibody in blocking buffer for 2
hours at RT, followed by conjugation with a secondary antibody linked to horseradish peroxidase in
blocking buffer for 1 hour at RT. Subsequently proteins were detected using the ECL detection
system.
Statistics
Results are presented as the mean ± SEM. Significance of observed differences between
experimental groups were tested by one-way ANOVA followed by Fischer's PLSD test, or in the
case of two groups by Student’s unpaired t test. In case of skewed data non-parametric methods
were used (Kruskal Wallis test and Mann Whitney U test). All statistical analyses were performed
using Statview 5.0 software (SAS institute, Cary, NC).
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RESULTS AND DISCUSSION
Growth factor effects on proliferation and differentiation of insulin producing cell lines (I)
The aim of the present study was to screen the effect of several peptide growth factors, hormones
and pharmacological agents on proliferation and differentiation of insulin producing INS-1 cell line.
INS-1 is a relatively differentiated rat insulin-producing cell line with substantially high level of
insulin expression and with glucose responsive insulin secretion (Asfari et al., 1992). We
hypothesized that the growth regulation of this cell line could thus resemble more closely the
regulation of primary b-cells than in more undifferentiated, glucose unresponsive lines, such as
RINm5F.
Table 2. Effect of studied growth factors on INS-1 proliferation and insulin
content (+ stimulation; - suppression; 0 no effect; N.D. not done)
Effect on proliferation Effect on insulin content
GH + 0
PRL + 0
IGF-1 + 0
IGF-2 + N.D.
VEGF + 0
PDGF 0 N.D.
NGF 0 N.D.
TGF-b 0 N.D.
Activin A - +
bFGF 0 N.D.
HGF 0 N.D.
EGF 0 N.D.
TGF-a 0 N.D.
NRG1 0 N.D.
Betacellulin + 0
Nicotinamide - +
Sodium butyrate - +
Nic. + Sod.but. - +
Vitamin D3 - +
Retinoic acid - 0
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In accordance with the hypothesis, several of the factors that were mitogenic to INS-1 cells had also
previously been demonstrated as beta cell mitogens in studies done with primary cells (Brelje and
Sorenson, 1991; Nielsen et al., 1992; Stout et al., 1997). From the factors that were tested only
betacellulin emerged as a novel beta cell mitogen. Interestingly, other members of the EGF family
tested (EGF, TGF-a) did not stimulate beta cell proliferation. Nicotinamide, sodium butyrate,
vitamin D3 analog and activin A inhibited INS-1 growth while increasing cellular insulin content.
Effects of EGF-family members on proliferation of less differentiated RINm5F cell line (Dereli et
al., 1988) was also studied. In contrast to the INS-1 line, betacellulin did not induce RINm5F cell
proliferation, whereas both EGF and TGF-a had a small stimulatory effect.
The results indicated that betacellulin is mitogenic for differentiated beta cells. This is in agreement
with studies showing that betacellulin is mitogenic for several cell types (Shing et al., 1993),
including fetal pancreatic epithelial cells (Demeterco et al., 2000). However, the potential of
betacellulin to induce proliferation of beta cells had not been demonstrated previously. Vitamin D,
activin A, nicotinamide and sodium butyrate emerged as potential factors for beta cell
differentiation. Effect of nicotinamide and sodium butyrate was additive, as has been shown to be
the case in primary fetal porcine cell cultures as well (Korsgren et al., 1993; Otonkoski et al., 1999).
Beta cell differentiation inducing effect of nicotinamide and activin A has also been demonstrated
previously (Mashima et al., 1996a; Otonkoski et al., 1993). Overall, the results thus suggest that the
INS-1 cell line is a useful model for studies of mechanisms regulating beta cell growth and
differentiation.
Expression of erbB receptors and ligands in pancreas (I, II, III)
After identification of betacellulin, a member of the EGF-family, as a novel beta cell mitogen, our
following aim was to study the expression profile of erbB receptors and ligands in the pancreas.
Expression of EGFR has been demonstrated throughout the developing human pancreas (Miettinen
and Heikinheimo, 1992), other erbBs are also expressed in the developing pancreas (Krahl et al.,
2000). Also several of the erbB ligands are present during the pancreas development. TGF-a
expression is abundant in the developing pancreas (Miettinen and Heikinheimo, 1992). Expression
of both betacellulin and HB-EGF has been demonstrated in the ductal cells of the developing
pancreas (Kaneto et al., 1997a; Miyagawa et al., 1999), and NRG4, a novel ligand of erbB4, is also
abundantly expressed in the pancreas (Harari et al., 1999).
To study the expression of erbBs in insulinoma cell lines and in primary pancreatic tissue, mRNA
was isolated and subjected to northern analysis. All known EGFR splice variants were expressed in
both INS-1 and RINm5F cells, as well as in the adult rat pancreas. ErbB2 and erbB3 were expressed
in the newborn mouse pancreas, in the adult rat pancreas, and in RINm5F cells, but not in INS-1
cells. Low level of erbB4 expression could be detected in the newborn mouse pancreas with
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northern analysis, but not in INS-1 or RINm5F cells. As the erbB4 expression was further studied
with immunohistochemical staining, it became evident that it is expressed in the ductal epithelial
tissue of the developing pancreas, and in the glucagon producing alpha cells of the adult pancreas.
A similar expression pattern was at the same time reported by others (Krahl et al., 2000).
Expression of erbB ligands was studied with RT-PCR and with northern analysis. A low level of
endogenous betacellulin expression was detected in both RINm5F and INS-1 cell lines. Betacellulin
was also expressed in the mouse pancreas throughout development. Also EGF, TGF-a, HB-EGF
and NRG4 were present in the mouse pancreas at all studied stages (e12.5, newborn and adult).
In summary, expression of erbB receptors and many of their ligands was observed in the developing
as well as in the adult pancreas, suggesting an important regulatory role for the EGF-family in
pancreas development and function.
Functional EGFR is essential for normal pancreatic development (II)
Since EGFR is expressed throughout the developing pancreas and since the pancreas also develops
through branching morphogenesis, we next wanted to study the role of EGFR in pancreas
development in vivo. For this purpose mice lacking functional EGFR were used. Inactivation of
EGFR leads to epithelial immaturity and to death within the first postnatal week of life. Epithelial
development of EGFR (-/-) mice is impaired in several organs (e.g. skin, gastrointestinal tract), and
organs developing via branching morphogenesis (e.g. lungs, mammary gland) are also affected
(Miettinen et al., 1995; Miettinen et al., 1997; Siblia and Wagner, 1995; Threadgill et al., 1995).
Analysis of EGFR (-/-) pancreases implicated impairment in islet cell migration and differentiation
in the absence of EGFR. In EGFR (-/-) embryos, the appearance of insulin-producing beta cells was
delayed, and also the number of glucagon-producing alpha cells was lowered. Though pancreases in
the EGFR (-/-) embryos were significantly smaller than in the wild type littermates, the differences
in blood glucose levels of the pups were insignificant, indicating that the early postnatal lethality
was likely not a consequence of inadequate insulin supplies.
Islet morphogenesis is disturbed in EGFR (-/-) mice (II)
All four major islet cell types were found in the EGFR (-/-) pancreases. However, their organization
as islets was disturbed. Whilst in the wild type pups the endocrine cells formed round pancreatic
islets separated from the pancreatic ducts, in the EGFR (-/-) pups the endocrine cells tended to stay
in streak-like structures associated with the ducts. In the newborn EGFR (-/-) pancreases over 60 %
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of the beta cells were duct-associated, whereas in the wild type pancreases only approximately 35
% of the beta cells remained in contact with ducts.
To find out the reason for the impaired islet formation in EGFR (-/-) pancreases, the expression of
both cell adhesion molecules, and ECM degrading proteases was studied. Cadherins are cell
adhesion molecules expressed in the developing pancreas and implicated in the islet formation
(Cirulli et al., 1994; Rouiller et al., 1991). Disruption of E-cadherin function leads to impaired
formation of compact islets due to problems in cell-cell adhesion (Dahl et al., 1996). However, no
difference was seen in the aggregation of individual islet cells to each other in mice lacking EGFR,
and also the E-cadherin-like immunoreactivity remained normal, indicating that cell-cell adhesion
within the islets was not affected in the absence of functional EGFR. Matrix metalloproteinases
(MMPS) are involved in the remodeling of the extracellular matrix during the embryogenesis
(Werb, 1997). MMPs are expressed in the pancreatic mesenchyme and it has been shown that
activation of MMP-2 is required for proper islet morphogenesis (Miralles et al., 1998; Reponen et
al., 1992). MMPs are upregulated by EGFR ligands (Kondapaka et al., 1997) and secretion of
MMPs has been shown to be diminished in cultured mandibular processes from EGFR (-/-)
embryos (Miettinen et al., 1999). Indeed, we found out that MMP-activity was also reduced in the
EGFR (-/-) pancreases. Both the total gelatinolytic activity and the amount of active form of MMP-
2 was reduced in late gestational EGFR (-/-) pancreases. Production of plasminogen activator
inhibitor-1 (PAI-1), an activator of MMPs, was instead increased in the EGFR (-/-) pancreases. It
thus appears that the reduced MMP-activity and the increased PAI-1 production are responsible for
the impaired islet formation seen in the EGFR (-/-) pancreases.
Beta cell proliferation and number are reduced in EGFR (-/-) mice (II)
The overall size of the EGFR (-/-) pancreases was reduced as compared to the wild type. Also the
development of beta cells was clearly delayed. Islet cell differentiation in the EGFR (-/-) embryos
was further studied using a whole-mount organ culture system (see methods). After the culture
period the EGFR (-/-) explants were clearly smaller and contained less ductal branches than the
wild type explants (number of luminal cross-sections 514±190 versus 1675±358, p<0.005).
Additionally, the proportion of insulin-producing beta cells was reduced significantly (27±6 %
versus 48±8 %, p<0.01), whereas the proportion of alpha cells was increased. Proliferation of
pancreatic beta cells was quantitated 2 hours after injection of the animals with BrdU. BrdU-
labeling index of beta cells was reduced significantly both in the newborn (2.6±0.4 % versus
5.8±0.9%, p<0.01) and in the one week old (1.4±0.5 % versus 4.8±0.6 %, p<0.01) EGFR (-/-) pups.
However, no difference could be detected in the number of apoptotic beta cells between the wild
type and EGFR (-/-) pancreases. Based on these findings, it appears that the reduced number of beta
cells in EGFR (-/-) mice is due to reduced proliferation and delayed differentiation.
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ErbB mediated signaling favors development of beta and delta cells and inhibits development
of alpha cells (III)
To further clarify the role of erbB-mediated signaling in pancreatic islet development, several erbB
ligands were introduced to whole-mount pancreatic organ culture. Pancreatic explants were cultured
for 5 days with EGF, HB-EGF, betacellulin, NRG4, or with plain medium. Addition of erbB
ligands to explant culture did not change the ratio of exocrine to endocrine cells. However, several
changes were observed within the endocrine cell population. Beta cell proportion was induced by
EGF, HB-EGF, and most significantly, by betacellulin. Proportion and number of delta cells was
increased by NRG4, a novel erbB4 ligand. Betacellulin was also able to induce delta cell number in
the explant culture. Proportion of glucagon producing alpha cells instead was significantly reduced
by addition of betacellulin, EGF, and NRG4. As a consequence an increase in beta to alpha cell
ratio and delta to alpha cell ratio was detected.
Both EGFR and erbB4 are required for differentiation of islet cells (II, III)
We had already previously demonstrated that beta cell differentiation is diminished in the absence
of functional EGFR (see above). We next wanted to block the signaling through erbB4 because it is
known that both betacellulin and NRG4 bind to it (Harari et al., 1999; Riese II et al., 1996) and they
were the most effective inducers of beta and delta cell differentiation in our explant model. ErbB4
was blocked indirectly, using soluble erbB4 receptor in the explant cultures. This soluble erbB4
binds its endogenous ligands as added to the culture system. Its addition to the explant culture for 5
days had no effect on beta to alpha cell ratio. The number of somatostatin producing delta cells
instead was dramatically reduced.
We next wanted to see if betacellulin and NRG4 effects could be overcome by inhibiting their
receptors. For this purpose betacellulin or NRG4 was added to the explant culture together with the
soluble erbB4. The delta-cell inducing effect of NRG4 could be blocked with the soluble erbB4,
whereas the beta-cell inducing effect of betacellulin could not be inhibited. EGFR is known to be
the primary receptor for betacellulin (Riese II et al., 1996). We therefore next investigated whether
the effect of betacellulin could be inhibited in the absence of EGFR. For this purpose betacellulin
was added to explants of EGFR (-/-) pancreases. Indeed, in the EGFR (-/-) cultures, betacellulin
failed to induce beta cell differentiation. These results demonstrate that betacellulin-induced
differentiation of beta cells is not mediated via erbB4. Instead, it appears that EGFR is the primary
receptor for betacellulin in the developing pancreas. Data obtained also further confirms that effects
of NRG4 are mediated exclusively via erbB4.
                     52
We had previously shown that both betacellulin and NRG4 are expressed endogenously in e12.5
mouse pancreas (see above). Inhibitory antibodies to betacellulin and NRG4 were added to the
explant culture to study the importance of endogenous betacellulin and NRG4 in islet cell
differentiation. Neutralizing anti-BTC antibody did not induce any significant response in the islet
cell differentiation in this model. NRG4 inhibitory antibody instead induced greater than 50 %
reduction in the development of somatostatin-expressing delta cells. These results indicate that
endogenous activity of betacellulin is not necessary for proper beta cell differentiation but could
perhaps be overcome by other EGFR ligands. NRG4 instead appears to be an important regulator of
delta cell differentiation.
Results obtained here demonstrate for the first time that EGF-family ligands can regulate the
lineage determination of pancreatic endocrine precursor cells. Both betacellulin and EGF favor beta
cell differentiation, NRG4 instead favors delta cell development. These results are in agreement
with findings demonstrating that betacellulin promotes beta cell differentiation (Li et al., 2001;
Mashima et al., 1996a). A functional role for NRG4 had not been demonstrated previously.
FGFR2b is required for proliferation and branching of the pancreatic ductal epithelium (IV)
Several FGFs and their receptors have been implicated in the pancreatic development (Le Bras et
al., 1998; Miralles et al., 1999). Especially FGF10, a ligand for FGFR2b, has been shown to be
important for growth and differentiation in the developing pancreas (Bhushan et al., 2001). Since
FGFR2b and its ligands have been shown to have a regulatory role in the development of organs
forming via branching morphogenesis (De Moerlooze et al., 2000; Sekine et al., 1999), and since
we were able to show FGFR2b expression throughout the developing pancreatic epithelium, we
next wanted to study the role of FGFR2b in the pancreas development. For this purpose mice
lacking functional FGFR2b were used. FGFR2b (-/-) mice survive to term, but die at birth due to
defective lung formation. FGFR2b (-/-) fetuses also lack limbs, eyelids, mammary glands and
anterior pituitary. Development of the salivary gland and inner ear are also impaired (De Moerlooze
et al., 2000; Mailleux et al., 2002; Pirvola et al., 2000).
FGFR2b (-/-) pancreases were greatly reduced in size, and both the proliferation and the number of
CK positive ductal cells was diminished. At e12 - 13 there was over 50 % reduction in both the
number of ductal cells (225±24 CK positive cells versus 566±94, p<0.02) and in their proliferation
index (2.5±0.6 % versus 5.0±0.7 %, p<0.04). Also at e15.5 a similar reduction in the number of
both CK positive cells (4373±430 versus 9602±2276, p<0.08) and in the number of luminal cross-
sections (380±11 ductal lumens / mm2 versus 626±32, p<0.002) was detected. These results clearly
demonstrate that both pancreatic duct cell proliferation and epithelial branching are impaired in the
absence of functional FGFR2b.
                     53
To further study the importance of FGFR2b-mediated signaling in the development of the
pancreatic ductal tree, FGFR2b ligands were introduced to the pancreatic explant culture system.
For this purpose wild type e12.5 pancreases were dissected as described (see methods) and cultured
with FGF7 or FGF10 for 24 hours, and the proliferation index of CK positive cells was counted.
The proportion of proliferating ductal cells was significantly increased after addition of either FGF7
(12.1±1.67 % versus 7.9±1.3 %, p<0.05) or FGF10 (11.9±1.96 % versus 7.9±1.3 %, p<0.05) as
compared to the control. These results are in agreement with previous studies showing that in the
absence of FGF10 pancreatic ductal branching is severely disturbed (Bhushan et al., 2001). Our
results also confirm the previous finding showing that the increased amount of FGFR2b ligands
induces pancreatic duct cell proliferation (Elghazi et al., 2002; Hart et al., 2001; Yi et al., 1994).
Pancreatic differentiation is not impaired in the absence of functional FGFR2b (IV)
Since FGFR2b (-/-) pancreases were clearly reduced in size and also had problems with ductal
branching and proliferation, we next wanted to study their endocrine and exocrine differentiation. It
had previously been suggested that FGFR2b is specifically required for the development of the
exocrine pancreas (Miralles et al., 1999), and that its over-stimulation is inhibitory to endocrine
pancreas differentiation (Elghazi et al., 2002). Previous studies have also demonstrated reduced
expression of PDX1 and subsequent problems in the endocrine differentiation in mice carrying a
null mutation for FGF10, a major ligand of FGFR2b (Bhushan et al., 2001). Based on these
findings, we expected FGFR2b (-/-) mice to have problems in both endocrine and exocrine
differentiation.
To study pancreatic differentiation, the level and expression pattern of several pancreatic
transcription factor genes was studied by in situ hybridization and northern analysis. Expression of
PDX1, p48, PAX6, ISL1 and NGN3 was detected in both mutant and wild type pancreases. The
relative expression level of an endocrine transcription factor NGN3, an exocrine transcription factor
p48, and a beta cell specific transcription factor NKX6.1 were all reduced by approximately 50 %
in the FGFR2b (-/-) pancreases. This suggested that there is no major defect in the differentiation of
endocrine or exocrine cell in the absence of FGFR2b. To confirm the results obtained from gene
expression analyses, we next stained sections from e15.5 and e18.5 mutant pancreases for endocrine
(insulin, glucagon, somatostatin and PP) and exocrine (amylase) markers. All these pancreatic
proteins were present in FGFR2b (-/-) pancreases, further indicating that differentiation of
pancreatic cell types does not require FGFR2b-mediated signaling. Finally, cell differentiation was
studied using the explant culture of both FGFR2b deficient and wild type pancreases. After five
days culture the total cell number in the FGFR2b (-/-) explants was significantly lower than in the
wild type explants (2737±525 versus 4073±540, p<0.05). The number (992±182 versus 2381±236,
p<0.001) and proportion (39±3.4 % versus 58 ± 3.7 %, p<0.01) of ductal cells was also clearly
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reduced. The relative proportion of endocrine cells however, was not significantly reduced, though
the beta cell number was lower than in wild type explants. The proportion of exocrine cells was
even higher in FGFR2b (-/-) explants than wild type. Addition of FGF7 or FGF10 to the wild type
explant cultures induced a small reduction in the number of endocrine cells. A similar effect of
FGF7 has previously been demonstrated in rat embryonic pancreatic epithelial culture (Elghazi et
al., 2002).
Taken together, the pancreatic phenotype of FGFR2b (-/-) mice indicates a crucial role for this
receptor in the proliferation of pancreatic ductal epithelial cells, as well as in the proper branching
of the pancreatic ductal tree. However, in contrast to previous findings (Miralles et al., 1999), we
show that FGFR2b is not required for differentiation of the exocrine pancreas. Also endocrine
differentiation can occur without functional FGFR2b, though proper amount of FGFR2b-mediated
signaling appears to be necessary for balanced development of the islet cells.
Mice lacking functional FGF10, which is considered as a major ligand for FGFR2b, also develop a
hypoplastic pancreas. Proliferation and branching of the pancreatic ductal epithelium is severely
disturbed in these mice. However, in addition to the branching defect, also the expression of several
pancreatic transcription factors is abolished and the endocrine differentiation is markedly reduced
(see Table 3). It is thus likely that FGFR2b is not the only mediator of FGF10 effects, since the
pancreatic phenotype of FGFR2b (-/-) mice is clearly less severe. FGFR1b, which also can bind
FGF10 (Lu et al., 1999), is highly expressed in the developing pancreatic epithelium (Cras-Méneur
and Scharfmann, 2002) and is thus the likely additional mediator of FGF10 effects (Figure 6).
Table 3. Comparison of FGFR2b (-/-) and FGF10 (-/-) pancreatic phenotypes
FGFR2b (-/-) FGF10 (-/-)
Pancreatic size Reduced Reduced
Ductal branching Reduced Reduced
Epithelial proliferation Reduced Reduced
Pdx1 expression Normal Reduced/Absent
Endocrine differentiation Slightly reduced Greatly reduced
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SUMMARY AND CONCLUSIONS
Due to recent success in clinical islet transplantation as a treatment for type I diabetes (Shapiro et
al., 2000), the search for new sources of transplantable insulin-producing cells has intensified. It has
been suggested that development of insulin-producing cells can be induced from embryonic stem
cells (Lumelsky et al., 2001; Soria et al., 2000), or from adult pancreatic ductal stem cells (Bonner-
Weir et al., 2000; Ramiya et al., 2000). Knowledge of the factors controlling development of beta
cell precursors and also the factors controlling differentiation of these precursors into mature beta
cells is essential before engineering of stem cells for the production of beta cells will be possible.
The present studies aimed to elucidate the role of some of the peptide growth factors involved in
these processes.
On the basis of the results obtained from this thesis study the following conclusions can be drawn:
• Differentiated insulin-producing cell lines appear to be suitable models for screening of growth
factors that regulate beta cell proliferation and differentiation. Betacellulin emerges as a
potential novel growth factor for the differentiated beta cell.
• All erbB receptors as well as several of the EGF-family ligands are present in the developing
pancreas. Signaling via EGF-receptor is essential for the migration of the developing pancreatic
islet cells through the surrounding mesenchyme. Functional EGFR is also needed for the proper
level of beta cell proliferation and differentiation. In the absence of EGFR signaling, the
endocrine precursor cells prefer to differentiate toward the alpha cell phenotype, whereas
increased amount of EGFR ligands EGF, HB-EGF and betacellulin shift the differentiation
balance toward the beta cell phenotype, betacellulin being the strongest inducer in this respect.
However, presence of betacellulin is not an absolute requirement for beta cell differentiation
indicating that redundancy within the EGF-family is quite abundant. EGFR ligands are involved
in the induction of beta cell differentiation from endocrine precursor cells.
• Although betacellulin has been shown to bind erbB4, the results obtained here indicate that its
effects in the pancreas are mediated solely through EGFR. Further studies are needed to
elucidate the pancreatic receptors and signaling pathways activated by betacellulin.
• NRG4 is an erbB4 ligand that is expressed predominantly in the pancreas. In the developing
pancreas NRG4 supports differentiation of the somatostatin producing delta cells and shifts the
differentiation balance of pancreatic endocrine precursors toward beta and delta cell lineages
instead of the alpha cell lineage.
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• ErbB4 is expressed abundantly in the epithelium of the developing pancreas. Its inactivation in
vitro inhibits the development of delta cells. However, the effect of erbB4 inactivation in the
developing pancreas in vivo has not been studied since embryos lacking functional erbB4 die
already prior to pancreas organogenesis. Further studies are thus needed to determine the exact
role of erbB4 in the developing pancreas.
• FGFR2b is expressed throughout the developing pancreas. Our results demonstrate that
FGFR2b mediated signaling is essential for pancreatic ductal branching and proliferation.
FGFR2b and its ligands seem to be important regulators of the pancreatic endocrine progenitor
cell mass.
• Since EGFR, erbB4, FGFR2b and their ligands are important regulators of pancreatic endocrine
progenitors, these factors could be used when producing insulin-producing cells from stem cells
or tissue-specific progenitor cells.
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